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Atrial fibrillation (AF) is the most 
common arrhythmia to occur after 
cardiac surgery. It is associated with 
postoperative complications including 
increased risk of stroke, prolonged 
hospital stay and increased costs. The 
study consisted of three randomized, 
prospective trials. In the first study 
intravenous metoprolol showed to be 
more effective than oral metoprolol 
in the prevention of AF after cardiac 
surgery. In the second study intrave-
nous hydrocortisone reduced the risk 
of postoperative AF by 37 % compared 
with placebo. In study three intrave-
nous metoprolol therapy showed to be 
as effective as intravenous amiodar-
one in the prevention of postoperative 
AF after cardiac surgery.
d
issertatio
n
s | 0
61 | Ja
r
i H
a
lo
n
en
 |  P
reven
tion
 of A
trial F
ibrillation
 A
fter C
ardiac S
u
rgery
Jari Halonen
Prevention of Atrial
Fibrillation After
Cardiac Surgery Jari Halonen
Prevention of Atrial 
Fibrillation After 
Cardiac Surgery
JARI HALONEN
Prevention of Atrial Fibrillation After
Cardiac Surgery
To be presented by permission of the Faculty of Health Sciences, University of Eastern Finland for
public examination in Auditorium 1, Kuopio University Hospital on Friday, June 3rd 2011, at 12
noon
Publications of the University of Eastern Finland
Dissertations in Health Sciences
Number 61
Heart Center Kuopio University Hospital, Institute of Clinical Medicine, School of Medicine,
Faculty of Health Sciences, University of Eastern Finland
Kuopio
2011

III
Kopijyvä Oy
Kuopio, 2011
Series Editors:
Professor Veli-Matti Kosma, M.D., Ph.D.
Institute of Clinical Medicine, Pathology
Faculty of Health Sciences
Professor Hannele Turunen, Ph.D.
Department of Nursing Science
Faculty of Health Sciences
Professor Olli Gröhn, Ph.D.
A.I. Virtanen Institute for Molecular Sciences
Faculty of Health Sciences
Distributor:
University of Eastern Finland
Kuopio Campus Library
P.O.Box 1627
FI-70211 Kuopio, Finland
http://www.uef.fi/kirjasto
ISBN (print): 978-952-61-0464-5
ISBN (pdf): 978-952-61-0465-2
ISSN (print):1798-5706
ISSN (pdf): 1798-5714
ISSN-L:1798-5706
IV
Author’s address: Heart Center Kuopio University Hospital
Institute of Clinical Medicine, School of Medicine
University of Eastern Finland
KUOPIO
FINLAND
Supervisors: Docent Tapio Hakala, M.D., Ph.D.
Department of Surgery, North- Karelia Central Hospital
Institute of Clinical Medicine, School of Medicine
University of Eastern Finland
KUOPIO
FINLAND
Professor Juha Hartikainen, M.D., Ph.D.
Heart Center Kuopio University Hospital
Institute of Clinical Medicine, School of Medicine
University of Eastern Finland
KUOPIO
FINLAND
Docent Mikko Hippeläinen, M.D., Ph.D.
Heart Center Kuopio University Hospital
Institute of Clinical Medicine, School of Medicine
University of Eastern Finland
KUOPIO
FINLAND
Reviewers: Professor Pekka Raatikainen, M.D., Ph.D
Department of Cardiothoracic Surgery
Tampere University Hospital Heart Center
TAMPERE
FINLAND
Docent Jari Laurikka, M.D., Ph.D
Department of Cardiothoracic Surgery
Tampere University Hospital Heart Center
TAMPERE
FINLAND
Opponent: Docent Jussi Rimpiläinen M.D., Ph.D
Department of Surgery
Institute of Clinical Medicine
University of Oulu
OULU
FINLAND
VHalonen, Jari. Prevention Of Atrial Fibrillation After Cardiac Surgery. 71 p.
University of Eastern Finland, Faculty of Health Sciences, 2011
Publications of the University of Eastern Finland. Dissertations in Health Sciences Number 61. 2011. 71 p.
ISBN (print): 978-952-61-0464-5
ISBN (pdf): 978-952-61-0465-2
ISSN (print):1798-5706
ISSN (pdf): 1798-5714
ISSN-L:1798-5706
ABSTRACT
Atrial fibrillation (AF) is the most common arrhythmia to occur after cardiac surgery. It is
associated with postoperative complications, including increased risk of stroke, prolonged
hospital stay and increased costs. The purpose of this study was to find a reliable, effective,
safe and well tolerated tools for the prevention of postoperative AF after cardiac surgery.
The study consisted of three prospective, randomized clinical trials.
In study I we randomized 240 patients to receive either oral or intravenous metoprolol for
48 hours after cardiac surgery. The incidence of postoperative AF was significantly lower in
the intravenous metoprolol group (16.8%) than in oral group (28.1%), (p=0.036).
Intravenous metoprolol administration was feasible and easy and turned out to be well-
tolerated in postoperative patients.
In  study  II  a  total  of  241  patients  were  scheduled  to  receive  either  intravenous
hydrocortisone or placebo postoperatively for 84 hours. The incidence of postoperative AF
was 30.0 % in the hydrocortisone group compared with 47.9% in the placebo group and the
relative risk reduction was 37%. Intravenous hydrocortisone therapy turned out to be well
tolerated. In addition, no serious complications were associated with intravenous
corticosteroid therapy.
In study III intravenous metoprolol therapy showed to be as effective as intravenous
amiodarone in the prevention of AF after cardiac surgery. Three hundred and sixteen
patients were randomized to receive either metoprolol or amiodarone intravenously
starting on the first postoperative morning after cardiac surgery. The incidence of
postoperative AF was 23.9% in the metoprolol group and 24.8% in the amiodarone group
with no statistical difference between the groups. However, because of the wide range of
the confidence intervals, we can not conclude that intravenous metoprolol and amiodarone
are equally effective in the prevention of AF after cardiac surgery.
In  summary,  we suggest  that  intravenous metoprolol  therapy should be  a  part  of  routine
medication to prevent AF in all patients undergoing cardiac surgery, unless
contraindicated. Moderate-dosage corticosteroid (hydrocortisone) should be considered for
the prevention of AF in high risk patients undergoing cardiac surgery. Amiodarone should
be used for the prevention of postoperative AF only if beta-blocker therapy is
contraindicated.
National Library of Medical Classification: QV 150, WG 169, WG 330, WO 184
Medical Subject Headings: Amiodarone; Anti-Arrhythmia Agents; Aortic Valve Surgery;
Arrhythmias; Atrial Fibrillation; Cardiac Surgical Procedures; Coronary Artery Bypass
Surgery; Hydrocortisone; Metoprolol; Postoperative; Prevention
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TIIVISTELMÄ
Eteisvärinä on yleisin sydänleikkauksen jälkeinen rytmihäiriö. Potilailla, joille tehdään sekä
ohitus- että läppäleikkaus samanaikaisesti, eteisvärinän esiintyvyys on suurempi kuin niillä
potilailla, joille tehdään pelkkä sydämen ohitusleikkaus. Eteisvärinän ilmaantuvuus on
suurin 2-4 leikkauksen jälkeisinä päivinä. Se on suurin ohitusleikkauksen jälkeisen
aivohalvauksen aiheuttaja sydän-keuhkokonetta käytettäessä. Eteisvärinä vaatii
ylimääräistä lääkehoitoa, pidentää sairaalassaoloaikaa ja lisää myös sydänleikkauksen
kokonaiskustannuksia. Joillakin potilailla eteisvärinä huonontaa sydämen pumppausta ja
hidastaa näin toipumista leikkauksesta.
Väitöskirjatyön tavoitteena oli selvittää ja kehittää sydänleikkauksen jälkeisen eteisvärinän
estohoitoa. Tutkimus koostuu kolmesta etenevästä ja satunnaistetusta potilastutkimuksesta.
Ensimmäisessä tutkimuksessa 240 potilasta satunnaistettiin saamaan joko suun kautta tai
suonensisäisesti annosteltavaa beetasalpaaja metoprololia 48 tunnin ajan sydänleikkauksen
jälkeen. Eteisvärinän esiintyvyys oli 16.8 % suonensisäisesti lääkettä saaneiden ryhmässä ja
28.1 % suun kautta lääkettä saaneiden ryhmässä. Ero potilasryhmien välillä oli tilastollisesti
merkittävä. Suonensisäisesti annosteltu metoprololi osoittautui turvalliseksi ja hyvin
siedetyksi estolääkitykseksi sydänleikkauksen jälkeisen eteisvärinän estossa.
Toisessa tutkimuksessa 241 potilasta satunnaistettiin saamaan joko suonensisäisesti
annosteltavaa hydrokortisonia tai lumelääkettä 84 tunnin ajan leikkauksen jälkeen.
Eteisvärinän esiintyvyys oli 30.0 % hydrokortisoni ryhmässä verrattuna 47.9 %:iin
lumelääkeryhmässä. Suhteellinen riskin väheneminen oli 37 %. Hydrokortisonihoito
osoittautui turvalliseksi eikä mitään vakavia haittavaikutuksia esiintynyt.
Kolmannessa potilastutkimuksessa verrattiin keskenään suonensisäisesti annosteltavaa
metoprololia ja amiodaronia. Sydänleikkauksen jälkeisen eteisvärinän esiintyminen oli
metoprololi ryhmässä 23.9 % ja amiodaroni ryhmässä 24.8 %. Ryhmien välillä ei ollut
tilastollisesti merkittävää eroa. Tilastollisen luottamusvälin laajuuden vuoksi ei voida
kuitenkaan suoraan tehdä johtopäätöstä, että hoidot olisivat olleet yhtä tehokkaita.
Kyseisten tutkimusten perusteella voidaan todeta, että suonensisäisesti annosteltava
metoprololi tulisi sisältyä eteisvärinän estolääkkeenä jokaisen sydänleikkauspotilaan
rutiinilääkitykseen, ellei lääkitykselle ole vasta-aiheita. Suonensisäisesti annosteltavaa
hydrokortisonia on aiheellista harkita sydänleikkauksen jälkeisen eteisvärinän estossa
korkean riskin potilaille. Amiodaronin käyttö sydänleikkauksen jälkeisen eteisvärinän
estossa tulisi rajoittaa ainoastaan niihin potilaisiin, joille beetasalpaaja lääkitys on vasta-
aiheinen.
Yleinen suomalainen asiasanasto: rytmihäiriö, eteisvärinä, sydänleikkaus, estohoito
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1 Introduction
Postoperative cardiac arrhythmias are frequent complications after cardiac and noncardiac
surgery. Postoperative atrial fibrillation (AF) is the most common postoperative arrhythmia
(Hollenberg and Dellinger 2000). AF complicates up to 8% of noncardiac surgery, and
approximately 12% of noncardiac thoracic surgical procedures (Polanczyk et al. 1998, Vaporciyan
et al. 2004).
AF is the most common arrhythmia to occur after cardiac surgery. The reported incidence
varies between 5.5% and 57% and is higher after combined coronary artery bypass grafting
(CABG) and valve surgery than after CABG alone (Buffolo et al. 1996, Patti et al. 2006, Cresswell
and Damiano 1993, Almassi et al. 1997). AF is especially common after mitral valve surgery,
occurring in as many as 64% of patients (Asher et al. 1998). Postoperative AF is the major cause
of stroke after non-pump CABG (Lahtinen et al. 2004). In addition, it is associated with a need for
additional treatment, prolonged hospital stay and increased costs (Creswell et al. 1993, Almassi
et al. 1997, Hakala et al. 2002a).
It has been shown that prophylactic medical therapy decreases the incidence of postoperative
AF after cardiac surgery. Beta blockers are recommended to be used for the prevention of
postoperative AF in all patients undergoing cardiac surgery (Dunning et al. 2006). However, the
bioavailability of orally administered beta-blockers is markedly reduced during the early phase
after CABG (Valtola et al. 2007).
Administration of corticosteroids has been found to reduce the incidence of recurrent AF
episodes in non-operative patients (Dernellis and Panaretou 2004). The effects of corticosteroid
treatment on postoperative AF have been addressed in a few studies, with divergent results
(Halvorsen et al. 2003, Prasongsukam et al. 2005).
Amiodarone has also been shown to be highly effective in the prevention of postoperative AF
after cardiac surgery. Both oral and intravenous amiodarone are effective in AF prophylaxis
(Daoud et al. 1997, Giri et al. 2001, Hohnloser et al. 1991, Guarnieri et al. 1999). However,
prophylactic treatment to prevent AF with intravenous amiodarone is not cost effective if given
to all patients (Mahoney et al. 2002). So far, no studies have compared the efficacy and safety of
intravenous beta-blockers and amiodarone in the prevention of AF after cardiac surgery.
In this work we have sought to find an effective, safe and well tolerated prevention therapy
for postoperative AF after cardiac surgery.

32 Review of the literature
2.1 GENERAL FACTS ABOUT ATRIAL FIBRILLATION
AF is classified as supraventricular arrhythmia, characterised by fast, unorganised
electrical activity and mechanical contraction of the atria. The atrial frequency is very
high  (450-600  min)  so  the  basic  ECG  line  is  uneven  and  the  normal  P  wave  cannot  be
distinguished. Due to the functional fluctuation of atrioventricular conduction together
with high atrial rate, the electrical activation and contraction frequency of the ventricles
are irregular (Raatikainen and Huikuri 2008).
Clinically,  it  is  reasonable  to  distinguish  five  types  of  AF  based  on  the  presentation
and duration of the arrhythmia: first diagnosed, paroxysmal, persistent, long-standing
persistent, and permanent AF.
(1) Every  patient  who  presents  with  AF  for  the  first  time  is  considered  to  be  a
patient with first diagnosed AF, irrespective of the duration of the arrhythmia or
the presence and severity of AF-related symptoms.
(2) Paroxysmal AF is self terminating, usually within 48 h. Although AF paroxysms
may continue for up to seven days, the 48 h time point is clinically important–
after this the likelihood of spontaneous conversion is low and anticoaculation
must be considered.
(3) Persistent AF is present when an AF episode either lasts longer than seven days
or requires termination by cardioversion, either with drugs or by direct current
cardioversion.
(4) Long-standing persistent AF has lasted for  1 year when it is decided to adopt a
rhythm control strategy.
(5) Permanent AF is said to exist when the presence of the arrhythmia is accepted
by the patient (and physician).
Lone AF is defined as AF occurring in otherwise healthy patients aged under 60 years
(Fuster et al. 2001, Kopecky et al. 1987). It occurs in fairly young patients and accounts
for about 30-45% of paroxysmal and 20-25% of permanent AF (Fuster et al.  2001).
AF  is  the  most  common  type  of  long-term  arrhythmia.  Its  occurrence  has  increased
rapidly during the last few years, and it has been estimated that the number of persons
suffering from it will increase 2-4-fold by the year 2050 (Miyasaka et al. 2006) and that
one person out of four aged over 40 years (26% of men and 23% of women) will develop
AF at some point in his/her life (Lloyd-Jones et al. 2004). Men are almost two times more
likely  than  women  to  develop  AF  (Fuster  et  al.  2006).  The  occurrence  of  AF  varies
considerably according to age and the patient’s other diseases. Its occurrence increases
with age. Approximately 0.4% of persons aged under 60 years and more than 10% of
those aged over 75 years suffer from it. Age is in fact the most important single factor
that exposes people to AF.
Among the cardiovascular risk factors associated with AF, hypertension is the most
common. Diastolic dysfunction of the ventricles does not allow their normal atrial filling.
The resultant back-pressure causes hypertrophy of cardiac myocytesproliferation of
fibrous tissue and decreases in intercellular coupling (Aidietis et al. 2007). AF is also
common in patients with coronary artery disease. However, ischemia of the atrium
rarely causes AF. Patients with coronary artery disease often exhibit left ventricular
dysfunction and hypertension with secondary abnormalities in the atrium (McCarthy
and Kruse 2007). Structural heart disease (aortic and mitral valve disease, hypertrophic
cardiomyopathy) is also strongly associated with AF (Dries et al. 1998, Olsson et al.
2006).
Of non-cardiac factors, hyperthyreosis and chronic obstructive pulmonary disease
(COPD) are the most important that increase the risk of AF (Fuster et al. 2001). The role
4of physical exercise is somewhat questionable. Intense cardiovascular exercise has been
shown to increase the risk of AF (Karjalainen et al. 1998). On the other hand, it reduces
blood pressure and can help in weight control.  The acute factors triggering temporary
AF are alcohol abuse, acute myocardial infarction, pericarditis, myocarditis and
pulmonary embolism (Fuster et al. 2001).
Although these risk factors and the ageing of the population are essentially connected
with the occurrence of AF, they only account for some of its increased occurrence. New
risk factors of AF have emerged during the last few years, such as overweight, sleep
apnea and metabolic syndrome. As the body mass index (BMI) increases, the occurrence
of AF increases progressively. Sleep apnea increases the risk of developing AF as well
(Schoonderwoerd et al. 2008).
The  hemodynamic  changes  caused  by  AF  are  affected  by  irregular  ventricular
response, specifically too fast ventricular response and the absence of atrial contraction
(Daoud et al. 1996, Clark et al. 1997). These factors reduce the heart’s minute volume
during AF by 20-30% as compared with sinus rhythm. If the contractility of the left
ventricle  is  normal,  this  does  not  play  a  major  clinical  role,  but  in  the  case  of
compromised LV systolic or diastolic function it can lead to hemodynamic collapse
(Alboni et al. 1995, Lau et al. 1990). In addition, a rapid ventricular response can lead to
congestive heart failure (tachycardiomyopathy) (Shinbane et al. 1997).
AF is an important risk factor that exposes people to cardiac embolisation. The
occurrence of ischemic stroke is 2-7 times higher among patients suffering from AF than
in  persons  of  the  same  age  who  are  in  sinus  rhythm.  In  addition,  in  AF  patients  with
rheumatic heart valve disease, the risk of an ischemic stroke increases 17-fold (Fuster et
al. 2001).
Although AF per se is seldom life threatening, extensive epidemiological
investigations  have shown that  the  mortality  of  patients  with  AF is  approximately  two
times higher  than that  of  persons  in  sinus  rhythm (Flegel  et  al.  1987,  Krahn et  al.  1995,
Benjamin et al. 1998).
2.2 ATRIAL FIBRILLATION AFTER CARDIAC SURGERY
2.2.1 Incidence
AF  is  the  most  common  arrhythmia  to  occur  after  cardiac  surgery.  The  reported
incidence of AF varies widely (between 5.5% and 57%) after cardiac surgery (Buffolo et
al. 1996, Patti et al. 2006). The incidence depends on the type of surgery, the patient’s
profile, the definition of AF used and the type of postoperative monitoring of the
patients. The incidence of AF after cardiac surgery in studies involving more than 1000
patients is presented in Table 1. Patients undergoing CABG and combined valve surgery
have a higher incidence of postoperative AF than patients undergoing CABG alone
(Almassi et al. 1997). It is of interest that there is a large variation in the reported AF
incidence in different parts of the world: South America–17.4%, Asia–15.7%, the United
Kingdom–31.6%, the USA–33.7%, Europe–34.0%, Canada–36.6%, and Central and
Eastern Europe–41.6% (Matthew et al. 2004).
2.2.2 Pathophysiology
Despite the new insights that have been gained into the mechanisms of AF, no specific
etiologic  factor  has  been  identified  as  the  sole  cause  or  perpetuator  of  the  arrhythmia.
The current evidence suggests that the pathophysiology of AF in general, as well as after
cardiac surgery, is multifactorial (Kourliouros et al. 2009). It is widely accepted that the
initiation and the perpetuation of AF requires a triggering factor (initiating event) and an
electrophysiological substrate (perpetuation) in the atria. The substrate is an
anatomical/physiological milieu in the atria which allows the wavefront to initiate AF,
and the triggers are factors firing these abnormal wavefronts (Allessie et al. 2001, Jurkko
2009).
5It  is believed that in most cases the pathophysiological mechanism of AF is re-entry.
The re-entry mechanism is facilitated when adjacent atrial regions have widely separated
refractory periods. In the atrial tissue, this non-uniform dispersion of refractoriness can
set up local areas of functional blocks, and the depolarizing wavefront faces both
refractory and excitable myocardium. It follows that the re-entry phenomenon is possible
and can lead to AF (Cox et al. 1991, Cox 1993, Konings et al. 1994). Cosio and coworkers
postulated that prolonged atrial conduction may also favour re-entry, and serve as a
substrate to AF (Cosio et al. 1983). The electrophysiological substrate is mandatory for
the development of AF. This can explain why some patients get and some do not get AF
after the same surgical procedure (Cox 1993). Findings of histopathologic abnormalities
such as myolysis and lipofuscin deposition in atrial tissue biopsies before
cardiopulmonary bypass in patients with postoperative AF supports this hypothesis (Ad
et al. 2001).
In addition to an electrophysiological substrate, a trigger is necessary for the initiation
of AF. As early as 1981 Cheung reported arrhythmogenic activity of pulmonary veins in
animal models of AF (Cheung 1981). Later it has been shown in non-operative patients
that pulmonary venous ectopic foci are common triggers for AF, and in some patients
the arrhythmia can be cured the catheter ablation of these foci (Jais et al. 1997,
Haissaguerre et al. 1998). This led to a reappraisal of the earlier anatomic work that
showed that muscle sleeves extend from the left atrium to the pulmonary veins (Nathan
et al. 1966). Since then, focal triggers have also been found in other areas in the atria
including the superior caval vein (Tsai et al. 2000), ligament of Marshall (Hwang et al.
2000), coronary sinus ostium, crista terminalis, and the left atrium posterior and anterior
free wall (Lin et al. 2003). Most commonly, the trigger exists in the pulmonary veins
(more than 90%). Based on the polarity of the ectopic beats in ambulatory ECG
recording, the triggering premature atrial complexes (PACs) have been reported to
originate from the left atrium in 74% and from the right atrium in 15% of cases, and in
11% the origin of the premature beats could not be determined (Vincenti et al. 2006).
2.2.2.1 Atrial ischemia
It has been suggested that in cardiac surgical patients atrial ischemia plays a significant
role in the development of the underlying substrate and as a triggering factor of AF.
During cardiopulmonary bypass the atrial tissue is warmer than the ventricular tissue,
and atrial electrical activity is often observed as a sign of inadequate atrial protection
(Smith et al. 1983, Tchervenkov et al. 1983, Chen et al. 1988). Tchervenkov and coworkers
showed that there is a correlation between postoperative atrial arrhythmias and
persistent electrical activity (Tchervenkov et al. 1983). On the other hand, in canine heart,
augmented atrial hypothermia during cardioplegia arrest had no effect on the atrial
effective  refractory  period  or  on  the  inducibility  of  AF  (Sato  et  al.  1992).  Kolvekar  and
coworkers showed that there is a strong association between arterial insufficiency to the
atrioventricular or  the sinoatrial node and the incidence of AF after cardiac surgery,
which suggests that atrial ischemia contributes to the the development of postoperative
AF after cardiac surgery (Kolvekar et al. 1997). However, atrial ischemia cannot be the
only triggering factor for AF after cardiac surgery.
62.2.2.2 Inflammation
The possible association of inflammation with postoperative atrial fibrillation after
cardiac surgery is composite. Cardiac surgery itself and extracorporeal circulation are
known to be associated with systemic inflammatory response (Hall et al. 1997, Wan et al.
1997),  which may play a  role  in  the  development  of  postoperative  AF.  Complement,  C-
reactive  protein  complex  levels,  and  the  number  of  white  blood  cells–markers  of
inflammatory reaction–are higher in patients who develop AF than in those who do not
(Bruins et al.1997, Lamm et al. 2006). Moreover, the efficacy of anti-inflammatory drugs
such as statins and steroids in the prevention of AF supports the association between AF
and inflammation (Savelieva et al. 2000).
2.2.2.3 Autonomic tone
The impact of variations in the autonomic tone on the heterogeneity of the
refractoriness of atrial and action potential duration shortening has been described in
animal models, suggesting a role of sympathetic and vagal stimulation in the initiation
and maintenance of AF (Liu and Nattel 1997). There are some human studies on
dynamic changes in autonomic tone before the onset of AF. They have demonstrated a
moderate increase in adrenergic tone with loss of vagal tone (Fioranelli et al.1999,
Dimmer et al. 1998), increased vagal activity (Zimmerman and Kalusche 2001, Herveg et
al. 1998) or a combination of primary increase in sympathetic activity followed by vagal
predominance (Bettoni et al. 2002). Kalman and coworkers showed that the mean
postoperative norepinephrine level (reflecting sympathetic nervous activity) was
significantly higher in patients with AF than in those without AF (Kalman et al. 1995). In
another study, Hogue and coworkers asessed the autonomic balance before the onset of
AF after cardiac surgery. Either low or high heart rate variability (HRV) was found
before the AF episode. They concluded that in some patients high sympathetic control
preceeds  the  onset  of  AF,  while  in  others  either  high  vagal  tone  or  dysfunctional
autonomic heart rate control contributes the AF onset (Hogue et al.1998).
In conclusion, the pathophysiology of AF after cardiac surgery is most likely
multifactorial. There has to be an underlying substrate which predisposes the patient to
AF, and a triggering factor which initiates the AF. This triggering factor can be surgical
trauma, inflammatory reaction due to surgical trauma and cardio-pulmonary bypass
(CPB), atrial ischemia or a change in the balance of cardiac autonomic regulation.
2.2.3 Risk factors
Old age also predicts AF in the general population (Feinberg et al. 1995) and it is the
most often reported independent risk factor for AF after cardiac surgery. The incidence
of AF after cardiac surgery increases by at least 50% per ten years of increased age
(Leitch et al. 1990, Matthew et al. 1996, Almassi et al. 1997, Mahoney et al. 2002). Aging
causes cardiac dilatation, myocardial atrophy, decrease of conduction tissue, and atrial
fibrosis (Lie and Hammond 1998, Kizman et al. 1990). These age-related changes may be
responsible for the increased risk for AF after cardiac surgery.
A preoperative history of AF is a factor which is consistently associated with the
incidence of AF after cardiac surgery. Patients with previous episodes of AF appear to
have  an  underlying  substrate  necessary  for  the  development  of  AF,  and  they  are  thus
susceptible to postoperative AF (Matthew et al. 1996, Hashimoto et al. 1991, Svedjeholm
and Håkansson 2000).
Hypertension is reported to be an independent predictor of postoperative AF in many
studies. This may be related to increased fibrosis and increased dispersion of atrial
refractoriness (Almassi et al. 1997, Svedjeholm and Håkanson 2000, Matthew et al. 2004,
Zacharias et al. 2005). On the other hand, in many well-conducted studies involving
large numbers of patients, hypertension has not been found to be an independent
7predictor of AF after cardiac surgery (Matthew et al. 1996, Mahoney et al. 2002, Hakala et
al. 2002a, Echahidi et al. 2007).
The blood supply to the right atrium, the sinoatrial node and the atrioventricular node
is conveyed mainly via the right coronary artery. It has been shown that obstructive
disease of the coronary arteries supplying the sinoatrial node and atrioventricular node
are  more common in  patients  developing AF after  CABG than in  those  who remain in
sinus rhythm (Mendes et al. 1995, Kolvekar et al. 1996, Pehkonen et al. 1998). Indeed,
stenosis of the sinoatrial artery or the right coronary artery has been found to be an
independent predictor of AF after CABG (Al-Shanafey et al. 2001, De Jong and Morton
2000).
Some studies  have found the  preoperative  use  of  digoxin to  be  an independent  risk
factor for AF after cardiac surgery (Creswell and Damiano 2001, Almassi et al. 1997,
Hakala et al. 2002a). Most probably, the indication for digoxin use rather than digoxin
itself explains this finding. It is apparent that digoxin has been used for heart failure and.
less compellingly, for the prophylaxis of AF. The use of digoxin is often associated with
sicker hearts.
Men appear more likely to develop AF after cardiac surgery than women. Sex
differences  in  ion-channel  expression  and  hormonal  effects  on  autonomic  tone  may
explain this difference between genders (Fuller et al. 1989, Aranki et al. 1996, Zaman et
al. 2000, Mahoney et al. 2002). However, there are also conflicting reports in which male
gender has not been an independent predictor of AF (Majahalme et al. 2002, Hakala et al.
2002a, Mathew et al. 2004, Zacharias et al. 2005, Echahidi et al. 2007).
Abrupt discontinuation of long-term beta blocker medication results in beta blocker
withdrawal effects. It is characterized by increased plasma catecholamine concentration.
The withdrawal effect has been proposed as a possible cause of AF after cardiac
operation when beta blocker medication has been stopped at the time of surgery (White
et al. 1984, Kalman et al. 1995). It has been demonstrated that the absorption of oral beta
blocker therapy immediately after cardiac surgery is very poor, which may further
strengthen the withdrawal effect (Valtola et al. 2007). COPD is a predictor of AF after
cardiac surgery. COPD patients have frequent premature atrial contractions, which can
act as triggers for the initiation of AF (Leitch et al. 1990, Creswell and Damiano 1993,
Almassi et al. 1997, Ad et al. 1999, Matthew et al. 2004, Zacharias et al. 2005).
Obesity and metabolic syndrome are reported to be independent risk factors for
postoperative AF after cardiac surgery. Echahidi and colleagues analyzed retrospectively
a total of 5058 patients who had undergone an isolated CABG procedure. They
demonstrated that obesity was a powerful and independent risk factor for the occurrence
of postoperative AF in patients older than 50 years. In the younger population, obesity
was not a risk factor, whereas metabolic syndrome remained an independent risk factor
for postoperative AF after cardiac surgery (Echahidi et al.  2007).
Several  other  factors  have  been  found  independently  to  predict  the  risk  of  AF  after
CABG: impairment of left atrial function (Leung et al. 2004, Benedetto et al. 2007), left
atrial enlargement (Ducceshi et al. 1999), previous myocardial infarction (Mahoney et al.
2002), resting pulse rate less than 80 beats per minute (Almassi et al. 1997),
precardiopulmonary heart rate over 100 beats per minute (Matthew et al. 1996),
peripheral vascular disease (Creswell and Damiano 1993), three vessel coronary artery
disease (Ducceschi et al. 1999), low body mass index (Jideus et al. 2000), and large body
surface area (Hakala et al. 2002a). In a study involving 4657 patients, congestive heart
failure was not a predictor of postoperative AF, but it was an independent risk factor for
recurrent AF after cardiac surgery (Mathew et al. 2004) The incidence and independent
predictors of AF after cardiac surgery according to studies involving more than 1000
patients are presented in Table 1 and Table 2.
Concerning  the  intraoperative  predictors  of  AF,  the  most  interesting  question  is  off-
pump versus on-pump surgery. Most of the studies comparing the incidence of AF after
8on-pump  and  off-pump  CABG  are  retrospective  and  involve  only  small  numbers  of
patients. Several studies have reported a lower incidence of AF after off-pump CABG
than after on-pump CABG (Allen et al. 1997, Abrey et al. 1999, Ascione et al. 2000).
However, several reports have found no difference between the incidence of AF after off-
pump and on-pump CABG (Siebert et al. 2000, Mueller et al. 2001, Hakala et al. 2004). In
a meta-analysis comparing the clinical outcome in 30 randomized trials and 3634
patients,  off-pump  CABG  reduced  the  risk  of  AF  compared  to  on-pump  CABG
significantly (RR 0.69; 95% CI 0.57-0.83) (Moller et al. 2008).
The type of cardioplegia seems not to play a role in the incidence of AF after cardiac
surgery (Butler et al. 1993, Pehkonen et al. 1995). Nor does the aortic cross-clamp time
seem to influence the incidence of AF after cardiac surgery, although there are some
reports with conflicting results (Mahoney et al. 2002, Aranki et al. 1996).
Table 1. The incidence of AF after cardiac surgery in
studies with at least 1000 patients.
Study Number of
patients
Incidence of AF*
(%)
Leitch et al. 1990 5807 17
Creswell et al.
1993
2833 32
Mathew et al.
1996
2048 26
Almassi et al.
1997
3126 28
Mahoney et al.
2002
8709 18
Hakala et al.
2002
3676 31
Matthew et al.
2004
4657 32
Zacharias et al.
2005
8051 23
Echahide et al.
2007
5085 34
*AF=Atrial fibrillation
9Table 2. A summary of the independent predictors of
postoperative AF after cardiac surgery. References are
the same as in Table 1.
Level of risk Risk factor for postoperative AF
High risk Previous episodes of AF
Mitral valve surgery
Combined valve and CABG surgery
Increased age
Low risk Male gender
Renal failure
COPD
PVD
Digoxin prior to surgery
CHF
Preoperative beta-blocker use
Smoking
Heart rate <80 or >100
Previous myocardial infarction
Low ejection fraction
Large body surface area
Beta-blocker withdrawal
Hypertension
Obesity
Metabolic syndrome
AF=Atrial fibrillation
CHF=congestive heart failure
COPD=chronic obstructive pulmonary disease
PVD =peripheral vascular disease
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2.2.4 Impact of atrial fibrillation on outcome after cardiac surgery
Although AF related to surgery is usually a temporary problem, it is associated with
increased morbidity, increased risk of stroke and a need for additional treatment. It also
prolongs hospital stay and increases costs.
The most serious complication of AF is stroke. Chung and colleagues found in their
retrospective analysis of 8,389 patients undergoing cardiac surgery that postoperative AF
independently increases the risk of embolic stroke 1.8-fold (Chung et al. 1995). Villareal
and colleagues reported in their study of 6500 patients undergoing cardiac surgery that
patients who had AF had a much higher incidence of stroke than patients who were in
sinus rhythm (5.2% vs. 1.7%, respectively, p=0.001) and also an increased risk of short
and long-term mortality (Villareal et al. 2004). Stamou and colleagues performed a
retrospective analysis of 19,500 patients undergoing CABG. A total of 333 patients had
suffered a stroke. Multivariant analysis showed that AF was an independent predictor of
stroke, increasing the odds of stroke to 1.7 (Stamou et al. 2001). Two other studies
indicated that the risk for perioperative stroke is 3-fold higher in patients with
postoperative AF than in patients who remained in sinus rhythm (Creswell et al. 1993,
Mathew et al. 1996). In a retrospective analysis of 2630 Finnish patients, 2% of those
undergoing on-pump CABG suffered a stroke. The researchers concluded that AF
occurring after CABG is a major determinant of postoperative stroke (Lahtinen et al.
2004).
Almassi  and  colleagues  found  that  hospital  mortality  (8.6%  vs.  3%)  and  6-month
mortality (9% vs. 4%) were significantly higher in patients with postoperative AF than in
patients with no postoperative AF after cardiac surgery (Almassi et al. 1997). In another
study, postoperative AF was associated with subsequent greater resource use as well as
with cognitive changes, renal dysfunction and infection (Mathew et al. 1996). In a
retrospective analysis of 3676 Finnish patients, postoperative AF was associated with
increased risk of stroke, confusion, gastrointestinal complications, readmission to
intensive care unit, and a longer intensive care unit stay (Hakala et al. 2002a).
The fact that postoperative AF lengthens hospital stay has been shown in many
studies (Creswell and Damiano 1993, Lazar et al. 1995, Mathew et al. 1996, Aranki et al.
1996, Chung et al. 1996, Borzak et al. 1998, De Jong and Morton 2000, Hakala et al.
2002a).  Furthermore, the impact of postoperative AF on the use of hospital resources is
substantial  and  was  estimated  to  lengthen  the  hospital  stay  by  4.9  days,  with  an  extra
cost of USD10,000-11,500 in hospitalization costs in the United States (Aranki et al. 1996).
In another study, a new onset AF after cardiac surgery increased the total cost of
treatment by more than USD6,000 (Hravnak et al. 2002). A third study showed that AF
lengthened the hospital stay after cardiac surgery by 3.2 days, and this was independent
of other variables (Tamis et al. 2000). In a study by Kim and colleagues, the impact of AF
after cardiac surgery on the length of hospital stay was found to be only 1-1.5 days (Kim
et al. 2001).
2.3 PREDICTING ATRIAL FIBRILLATION AFTER CARDIAC SURGERY
2.3.1 Standard 12-lead ECG
The  findings  concerning  standard  ECG  as  a  tool  for  preventing  the  risk  of  AF  after
cardiac surgery are conflicting. Buxton and Josephson reported that patients developing
AF after CABG had a significantly longer P-wave duration in standard ECG than
patients who remained in sinus rhythm (Buxton and Josephson 1981). Chang and
colleagues reported that the presence of prolonged P-wave duration (>100ms in lead II)
was an independent predictor of AF with a 1.9-fold risk compared to a P-wave duration
of less than 100 ms (Chang et al. 1999). The P-wave duration in both signal–averaged
ECG and and surface ECG has been reported to be prolonged in patients who develop
AF after CABG (Dimmer et al. 1998). In that study, a significant correlation was found
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between the P-wave duration in standard ECG and signal-averaged ECG. In the study of
Aytemir and colleagues, P-wave duration in lead II and signs of left atrial enlargement
were  determined  from  standard  ECG.  They  found  that  left  atrial  enlargement  (relative
risk 2.7-fold) but not the P-wave duration was an independent predictor of AF after
CABG (Aytemir et al. 1999). Passman and colleagues found that P-wave duration in lead
V1 was an independent predictor of AF after CABG (Passman et al. 2001). The age-
adjusted odds ratio (OR) for the development of AF was 2.30 when the P-wave duration
in lead V1 was  > 110 ms. Tsikouris and colleagues measured the P-wave dispersion and
maximum P-wave duration in the 12 lead ECG preoperatively and on postoperative
days 1- 4 in patients undergoing open-heart surgery. They found that the P-wave
dispersion was greatest on days 2 and 3, and  atrial conduction time was greatest on day
3 after open–heart surgery, timings that coincide with the time of greatest risk of AF
(Tsikouris et al. 2001).
Stafford and colleagues analysed lead II P-wave duration, total P-wave duration, and
P-terminal force in standard ECG. The total P wave duration was the time from the
earliest onset of P-wave activity in any of leads I,  II  or III  to the last P-wave activity in
any of these leads. No significant differences were observed in any of these variables
between patients who developed AF after CABG and those who did not (Stafford et al.
1997). Similarly, another study found no difference in the P-wave duration on standard
ECG between patients with and those without AF after CABG (Caravelli et al. 2002).
In conclusion, the sensitivity and specificity of signal–averaged ECG and standard ECG
in predicting the risk of AF after cardiac surgery are not sufficient. Thus, they do not play
a role in clinical practice and decision making.
2.3.2 Signal average P- wave ECG
Several studies have assessed the feasibility of signal–averaged ECG in evaluating
patients at high risk for postoperative AF after cardiac surgery. In particular, abnormal
atrial conduction, defined by a prolonged filtered P-wave duration in signal–averaged P-
wave analysis, has been shown to be an independent predictor for postoperative AF.  In
these studies, the abnormal P-wave duration varied from 122 to 155 ms. The sensitivity
of the signal–averaged P-wave duration in identifying patients who developed AF
postoperatively has been 68–86%, with a specificity of 39–88%. The positive and negative
predictive values varied from 34 to 76% and from 83 to 85%, respectively (Steinberg et al.
1993, Klein et al. 1995, Zaman et al. 1997, Stafford et al. 1997, Aytemir et al. 1999,
Caravelli et al. 2002, Bodeus et al. 2006, Hayashida et al. 2005).
The predictive value of the signal–averaged P-wave duration is further improved
when it is combined with ejection fraction. In patients with P-wave duration >140 ms and
ejection fraction <40% the risk of postoperative AF was nearly nine times higher than in
patients with a normal P-wave duration and normal ejection fraction (Hutchinson et al.
1996). Similarly, the combination of P-wave duration (>155 ms) and low serum
magnesium concentration (<0.7mmol) on the first postoperative day increased the
positive predictive value from 37% to 62% (Zaman et al. 1997). When the P-wave
duration (>122.3ms) and the precence of a right coronary artery lesion were combined,
the positive and negative predictive values were 81% and 76% respectively (Aytemir et
al. 1999).
2.3.3 Heart rate variability
Two studies have evaluated heart rate variability (HRV) immediately prior to the
onset  of  AF  after  CABG.  Dimmer  and  colleagues  found  that  the  low  frequency/high
frequency (LF/HF) ratio was initially significantly lower in the AF group compared with
the SR group, but the LF/HF ratio increased before the initiation of AF in AF patients.
This study showed that changes in autonomic tone rather than autonomic tone itself are
important indicators of AF onset (Dimmer et al. 2003). Hogue and colleagues observed
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either lower or higher measures of HRV before AF after CABG, which is consistent with
divergent  autonomic  conditions  before  AF  onset.  They  argue  that  in  some  patients,
increased sympathetic tone is present before AF, whereas Hogue and colleagues
reported that either high vagal tone or dysfunctional autonomic heart rate control was
present before AF onset (Hogue et al.1998).
Two studies evaluated the use of 24-h preoperative Holter monitoring and the risk of
postoperative AF after CABG. Frost et al. analyzed the HRV in 102 CABG patients. They
calculated that the percentage of successive RR interval differences was >6% (vagal
index)  and  found  it  to  be  significantly  lower  in  patients  developing  AF,  whereas  the
overall  HRV  was  the  same  in  the  AF  and  SR  groups.  They  concluded  that  an  isolated
reduction  in  the  basic  vagal  modulation  causes  an  autonomic  imbalance  in  patients
prone to develop AF after CABG (Frost et al. 1995). Jideus et al. found no difference in
preoperative time and frequency domain variables between patients who developed AF
and those who remained in SR (Jideus et al. 2001). However, they found that a
diminished circadian variation in HRV before surgery indicated a propensity for AF.
These studies were based on the 24-h monitoring of HRV. Long-term measures of HRV
represent responses of cardiac autonomic regulation to challenges of daily life, and the
interpretation of these findings is limited by the fact that these challenges are not
controlled, the recordings are not stationary and the recording conditions cannot be
standardized. These standardization problems could be solved by using an assessment
of short-term HRV.
Hakala et al. showed that a short-term preoperative analysis of HRV under
standardized physiological conditions could not reliably identify patients at high risk of
AF after CABG. Heart rate, the standard deviation of normal to normal RR interval
(SDNN) or the square root of the mean squared differences of adjacent RR intervals
(RMSSD) did not differ significantly between the AF and SR groups when tested either
with spontaneous or controlled breathing. None of the spectral analysis measures (total
power, very low frequency power, low frequency power, or high frequency power)
differed significantly either. In both groups, heart rate increased and SDNN decreased
after tilting to the upright position, but there was no statistical difference between the
groups. In power spectral analysis, total power and all of its components decreased after
tilting both in the AF and SR groups but there was no statistical difference between the
groups. Neither there was any statistical difference between the groups in the LF/HF
ratio (Hakala et al. 2002b).
Tarkiainen and colleagues investigated whether there are constant preoperative
alterations in the nonlinear R-R interval dynamics that associate with the risk of
postoperative  AF  in  patients  with  preserved  left  ventricular  function.  They  found  that
preoperatively altered nonlinear R-R interval dynamics was an independent predictor of
postoperative atrial fibrillation and might become a useful tool for the risk assessment of
atrial fibrillation (Tarkiainen et al. 2008).
2.3.4 Left atrial enlargement
Some studies have found that left atrial enlargement predicts AF after open heart
surgery. Ducceschi et al. reported that left atrial enlargement in transthoracic
echocardiography was the strongest predictor of postoperative AF in CABG patients.
Left atrial enlargement was defined as an anteroposterior M-mode diameter >41mm
measured in the parasternal long-axis view. They found left atrial enlargement in 21% of
patients who remained in SR and in 70% of patients who developed AF (Ducceschi et al.
1999). This was confirmed by Giri et al. in patients undergoing CABG, valve surgery or
both (Giri et al. 2001). Asher et al. found left atrial enlargement to be an independent
predictor of AF early after cardiac valvular surgery. The limit for left atrial enlargement
was 40 mm in their study (Asher et al. 1998). In a prospective study by Hakala et al. left
atrial enlargement was an independent predictor for postoperative AF in patients
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undergoing elective CABG surgery. Each ingreasing cm2 of left atrial area increased the
risk of AF 1.29-fold (p=0.01, 95 CI 1.05-1.57) (Hakala et al. 2002c). This was confirmed in
another study of CABG patients (Dogan et al. 2007). There are also some contrary
findings. In two studies, left atrial enlargement was not found to be an independent
predictor of AF after cardiac surgery (Stafford et al. 1997, Jideus et al. 2000). Another
study by Zaman et al. did not reveal any difference in left atrium size between patients
who developed AF and those who remained in SR, but their study involved only 64
patients, who were a subgroup of a larger study population (Zaman et al. 2000).
2.3.5 Natriuretic peptides
Atrial natriuretic peptides (ANP) are produced primarily in the cardiac atria, and the
dominant stimulus for their release is increased atrial wall tension, reflecting increased
intravascular volume. ANP is synthesised from prohormones. Endocrinological active
peptide ANP and its N-terminal prohormone fragments (N-ANP) are found in plasma.
Brain natriuretic peptide (BNP) is synthesised from prohormones mainly in ventricles
(Levin et al. 1998). AF has been shown to be an independent determinant of high N-ANP
levels, but high BNP levels are not uniquely associated with AF (Rossi et al. 2000).
Longstanding AF causes  depletion of  N-ANP in  patients  with  congestive  heart  failure.
This  finding  suggests  that  longstanding  AF  leads  to  an  impaired  ability  of  the  atria  to
produce these hormones because of the inherent degenerative processes (van der Berg et
al. 2002). ANP or N-ANP levels are not predictors of conversion to SR in non-operative
patients (Hornestam et al. 1998, Abrad et al. 2001). However, an elevated ANP level is an
independent predictor of AF paroxysm in chronic heart failure. ANP levels higher than
60pg/ml had a hazard ratio of 8.6 for AF in 75 patients who had congestive heart failure
but no previous AF (Yamada et al. 2000).
In a prospective study by Akazava et al. 150 patients without a previous history of AF
undergoing elective off-pump CABG, plasma BNP levels were measured preoperatively.
Twenty-six patients (17.3%) developed postoperative AF. Univariate analysis revealed
that the preoperative plasma BNP level was an independent predictor of postoperative
AF (Akazawa et al. 2008). In another study, 187 patients without a previous history of AF
undergoing CABG were studied. Postoperative AF was documented in 80 patients
(42.8%) and preoperative plasma BNP levels were higher in patients developing
postoperative AF (615 vs. 444 pg/ml, P=0.005). They concluded that an elevated BNP
level is a strong and independent predictor of postoperative AF (Watzni et al. 2004).
However, a study of 398 consecutive patients found that the preoperative BNP level does
not predict the risk of AF after CABG (Tavakol et al. 2009).
Hakala et al. studied 88 elective CABG patients, measuring N-ANP and BNP
preoperatively. Thirty-one patients (35.2%) developed AF postoperatively. In the
univariate analysis, atrial peptides were associated with the development of
postoperative AF, but in the multivariate analysis only age and left atrial enlargement
were independent predictors for postoperative AF. However, atrial peptides were
associated with age, but did not independently predict postoperative AF. They
concluded that the wide variation in the peptide levels renders the implementation of
this measure in clinical practise superfluous (Hakala et al. 2002c).
2.3.6 Induction of atrial fibrillation
Some studies have used intraoperative screening tests to determine the risk of
postoperative AF after cardiac surgery. Lowe et al. studied the value of intraoperative
induction with alternating current of AF in 50 patients undergoing CABG. The
intraoperative induction of AF had a sensitivity of 94%, but the specificity was only 41%
for the occurrence of postoperative atrial arrhythmias. The negative and positive
predictive values of the tests were 93% and 47%, respectively (Lowe et al. 1991).
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In another study, a new intraoperative high-rate atrial pacing test was developed to
determine the risk for postoperative AF (Hakala et al. 2002d). After cannulation but
before the initiation of cardio pulmonary bypass (CPB), two pacing wires were placed on
the lateral surface of the right atrium, which was paced with a rate of 200 beats per
minute for 10 seconds. If this did not induce AF, high rate pacing was repeated with a
rate of 250 and 300 beats per minute. This test was performed in 80 patients undergoing
CABG. High rate atrial pacing induced AF in 27 patients (33.7%). Of the 28 patients who
experienced AF during the postoperative period, 17 were inducible in the atrial pacing
test (sensitivity 0.61). Of the 52 patients who did not develop AF postoperatively, 42
were not inducible in the atrial pacing test (specificity 0.81).  The positive and negative
predictive accuracy of the test were 63% and 79%, respectively. The investigators
concluded that high rate atrial pacing during CABG is a safe, simple and fast method
with a reasonable accuracy to predict postoperative AF (Hakala et al. 2002d).
2.4 PREVENTION OF ATRIAL FIBRILLATION AFTER CARDIAC
SURGERY
2.4.1 Beta-blockers
The effectiveness of beta-blockers in the prevention of AF after cardiac surgery has
been demonstrated in numerous studies. The results of four meta-analyses have shown
that prophylactic beta-blocker therapy reduces the incidence of AF after cardiac surgery
(Table 3). According to the meta-analysis, the type of beta-blocker or the dose have no
influence on the effectiveness of the prevention.
Yaziciolglu and co-workers reported that combining digoxin with atenolol is more
effective than atenolol alone (Yaziciolglu et al. 2002). The study by Balcetyte-Harris et al.
compared the efficacy and safety of intravenous beta-blocker (esmolol) and oral beta-
blocker (Balcelyte-Harris et al. 2002). The study was terminated when interim analysis
revealed a significantly greater incidence of adverse effects in the group receiving
intravenous  esmolol,  and  the  lack  of  any  reduction  in  AF  incidence.  The  efficacy  and
safety of intravenous propranolol was studied earlier by Abel et al. (Abel et al. 1983).
They reported that propranolol was more effective in AF prophylaxis than placebo.
However, a trend toward more frequent adverse effects in the propranolol treatment
group was reported (Abel et al. 1983).
Valtola and colleagues evaluated the bioavailability of perioperative metoprolol
tablets  in  CABG patients  in  their  pharmacokinetics  study.  Their  study showed that  the
bioavailability  of  metoprolol  is  markedly  reduced  when  administered  in  tablet  form
during the early phase after CABG (Valtola et al. 2007).
In conclusion, the effectiveness of beta-blockers in the prevention of AF after cardiac
surgery is confirmed. Indeed, according to the recent guideline, beta-blocking
prophylaxis should be given to every patients undergoing cardiac surgery when there is
no contraindications for its use.
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2.4.2 Sotalol
Sotalol is a Class III antiarrhythmic agent with beta-receptor and potassium channel
blocking properties. These properties theoretically prevent postoperative AF by
prolonging refractoriness and blocking neurohormonal activation. The effectiveness of
sotalol has been demonstrated in several placebo-controlled trials (Pfisterer et al. 1997,
Weber et al. 1998, Gomes et al. 1999). The effectiveness of sotalol has also been compared
with  that  of  other  beta-blockers  in  three  randomized  trials.  In  the  trial  by  Parikka  and
coworkers, sotalol 75 mg/d was compared with metoprolol 120 mg/d in 191 patients who
underwent coronary artery bypass surgery. AF occurred in 32% of the metoprolol group
and 16% of the sotalol group. No proarrhythmic effects of sotalol were found during the
study (Parikka et  al.  1998).  Similarly,  Janssen and co-workers  and also  Suttorp and co-
workers found that sotalol was more effective than metoprolol (Janssen et al. 1986) or
propanolol (Suttorp et al. 1990) in the prevention of AF. Two other studies evaluated the
use of sotalol as monotherapy in patients undergoing cardiac surgery (Jaguet et al. 1994,
Auer et al. 2004). In these studies sotalol reduced the incidence of postoperative AF by
41-93%. A serious limitation in some of the studies was that preoperative beta-blocker
therapy was not continued in the control groups, predisposing them to higher rates of
AF after cardiac surgery. Forlani et al. randomized 207 concecutive CABG patients to
receive either magnesium, sotalol, both magnesium and sotalol or no antiarrhythmic
agents. They found that both sotalol and magnesium were effective in reducing the risk
of postoperative AF, and that combination therapy of these drugs was the most effective
(Forlani et al. 2003).
A meta-analysis of eight trials and 1294 patients assessed the effect of sotalol in the
prevention of AF after cardiac surgery. Individual study sample size varied from 36 to
300 patients. The meta-analysis demonstrated that sotalol reduced the incidence of
postoperative AF (OR, 0.35; 95% CI, 0.26-0.49) with no significant heterogeneity between
trials (Crystall et al. 2002). Another meta-analysis of 14 trials compared 2583 patients
receiving sotalol with 2622 patients receiving either placebo of conventional beta-
blockers. Overall, AF was reduced from 33.7% to 16.9% (OR 0.37, 95% CI 0.29-0.48). On
the other hand, significantly more patients were withdrawn from treatment in the sotalol
groups  than  in  the  placebo  groups  because  of  side  effects,  predominantly  hypotension
and bradycardia (Burgess et al. 2006).
Sotalol is potentially a proarrhythmic agent. In non-surgical patients the
proarrhythmic risk has been reported to be 4.3–5.9% (Soyka et al. 1990). Because of the
potential proarrhythmic effects of sotalol, ordinary beta-blockers are considered to be a
safer alternative than sotalol in the prevention of AF after surgery.
Table 3. Beta-blockers in the prevention of postoperative AF. A summary of meta-analyses of
randomized controlled trials.
Study Number of
studies
Number of
patients
AF% in
treatment
group
AF% in
control
group
OR; 95% CI
Andrews et al. 1991 18 1549 9 34 0.28; 0.21-0.36
Kowey et al. 1992 7 1418 10 20
Crystal et al. 2002 52 3840 19 33 0.39; 0.28-0.52
Burgess et al. 2006 31 4452 17 31 0.36; 0.28-0.47
AF=atrial fibrillation
CI= confidence interval
OR= odds ratio
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2.4.3 Amiodarone
Amiodarone is a Class III antiarrhythmic agent that inhibits multiple ion channels
(potassium and calcium) and adrenegic receptors ( and ). Amiodarone has been
shown to be useful in the prevention of postoperative AF. Studies in which amiodarone
was given orally starting one or several days preoperatively report that the incidence of
AF fell from 53% to 25% and from 38% to 22.5%, or the length of AF shortened when
compared with placebo (Daoud et al. 1997, Giri et al. 2001, White et al. 2002)
The effect of intravenous amiodarone therapy has also been evaluated. In these
studies the amount of amiodarone given has varied between studies. Amiodarone has
reduced the incidence of AF by 25-76% compared with placebo (Hohnloser et al. 1991,
Guarnieri et al. 1999, Lee et al. 2000, Giri et al.l 2001,Yazigi et al. 2002).
A few studies have not found amiodarone to be effective in the prevention of AF after
cardiac  surgery.  However,  the  number  of  patients  has  been  small  in  these  studies  and
they are underpowered to draw any conclusion (Redle et al. 1999, Dörge et al. 2000,
Treggiari-venzi et al. 2000).
A meta-analysis of 9 randomized trials showed that amiodarone therapy decreased
the incidence of AF from 37% to 22.5% (Crystal et al. 2002). However, amiodarone was
not found to be a cost-effective alternative for all patients undergoing coronary artery
bypass  surgery.  In  contrast,  elderly  patients,  patients  with  COPD  and  patients
undergoing both bypass and valvular surgery possibly benefit from amiodarone
(Mahoney et al. 2002). Other meta-analyses have also examined the feasibility of
amiodarone in the prevention of AF after cardiac surgery (Burgess et al. 2006, Aasbo et
al. 2005, Gillespie et al. 2005, Patel et al. 2006). Aasbo and colleagues combined the data
of 10 trials and reported a significant reduction in the incidence of AF or flutter (RR 0.64;
95% CI 0.21 to 0.76) with amiodarone therapy versus placebo (Aasbo et al. 2005). The
length of hospital stay was also significantly reduced with amiodarone. Gillespie et al.
reported in their meta-analysis of 15 trials a 50% reduction in postoperative AF with
amiodarone treated patients versus placebo treated patients (Gillespie et al. 2005). The
type of surgery, use of beta-blockers, and route of the amiodarone administration did not
have signifcant effects on the overall results of the analysis.
The safety of amiodarone was evaluated in a meta-analysis of 18 randomized
controlled trials and 3408 patients (Patel et al. 2006). The authors reported that the use of
amiodarone was associated with increased risk of bradycardia and hypotension,
although the risk of heart block, nausea, and myocardial infarction was not significantly
increased. The rates of bradycardia and hypotension were higher in studies using
intravenous amiodarone than in those using oral amiodarone. Table 4 presents the
results of meta-analyses of amiodarone in the prevention of AF after cardiac surgery.
Amiodarone cannot be recommended to be given routinely to all patients undergoing
heart surgery. On the other hand, according to the guidelines amiodarone therapy can be
considered for patients who are at an especially high risk (old patients, previous
episodes of AF, valve surgery) for developing AF postoperatively (Dunning et al. 2006).
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Table 4. Amiodarone in the prevention of atrial fibrillation after cardiac surgery. Meta–
analyses of randomized controlled trials.
Study Number of
studies
Number of
patients
AF in
treatment
group %
AF in placebo
group %
OU ; 95% CI
Crystal et al
2002
9 1384 22.5 37.0 0.48 (0.37-0.61)
Aasbo et al
2005
10 1744 22.2 34.7 0.64 (0.55-0.75)
Gillespie et al
2005
15 1512 19.9 32.9 0.50 (0.42-60.0)
Burgess et al
2006
18 3295 19.8 33.2 0.48 (0.40-0.57)
2.4.4 Magnesium
Low serum magnesium level is common after cardiac surgery (Fanning et al. 1991,
England et al. 1993). Low magnesium concentration is also an independent determinant
of AF after CABG (Treggiari-Venzi et al. 2000, Zaman et al. 1997). Moreover, this
association has been noted even when serum magnesium concentrations do not correlate
with intracellular or myocardial magnesium concentrations (Reinhart 1991).
Administration of intravenous magnesium has been shown to decrease the incidence
of AF after cardiac surgery (Fanning et al. 1991, Colguhoun et al. 1993, Wistbacka et al.
1995, Toraman et al. 2001, Wilkes et al. 2002 Jensen et al. 1997). In a randomized study in
which patients received either magnesium 178 mEq or placebo for 4 days following
surgery,  the  incidence  of  AF  was  lower  in  the  magnesium  group  than  in  the  placebo
group (Fanning et al. 1991). Wistbacka and co-workers evaluated the role of magnesium
dosage in the prevention of AF. In the high dose magnesium group (4.2 g before surgery,
11.9 g infusion by the morning of the first postoperative day and 5.5 g on the following
day) the incidence of AF was lower than in the low dose group (4.2 g, 2.9 g, 1.4 g).
Magnesium concentration was also normal in patients receiving the low dose
magnesium (Wistbacka et al. 1995). In a trial in which 200 CABG patients were
randomized to receive either 6 mmol/days of magnesium or placebo on the day before
surgery  and  the  first  four  days  after  surgery,  the  incidence  of  AF  was  only  2%  in  the
magnesium group, but 21% in the placebo group (Toraman et al. 2001). In contrast,
Jensen and co-workers found that magnesium decreased the duration of AF and flutter,
but did not decrease the incidence of AF (Jensen et al. 1997). In a retrospective study
patients undergoing off-pump CABG who received magnesium were less likely to
experience postoperative AF than control patients (12% vs. 29%, respectively) (Maslow et
al. 2001).
Negative studies about the preventive effect of magnesium on postoperative AF have
also been published. In a study by Parikka, 70 mmol of magnesium was given during the
first 48 h after surgery. Magnesium did not reduce the incidence of AF, and surprisingly
a high serum magnesium level was found to increase the incidence of AF (Parikka et al.
1993). Another study in which 14.4 g of magnesium was given during the first 24 h
postoperatively found no effect of magnesium on the incidence of supraventricular
tachycardias (Karmy-Jones et al. 1995).
In a meta-analysis of 20 studies and 2490 patients, magnesium decreased the incidence
of postoperative atrial fibrillation from 28% to 18% (Miller et al. 2005). The effectiveness
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of magnesium has been shown also in other meta-analyses (Shiga et al. 2004, Alghamdi
et al. 2005).
In conclusion, it seems that magnesium reduces the risk of AF after cardiac surgery.
The optimum dose remains to be determined. There is no evidence that magnesium
would be of benefit for patients who already are on beta-blocker medication.
2.4.5 Corticosteroids
Cardiac  surgery  with  extracorporeal  circulation  is  known  to  be  associated  with  sys-
temic inflammatory response (Hall et al. 1997, Wan et al. 1997), which may be in part
responsible for postoperative AF. Complement, C-reactive protein complex level, and
number of white blood cells (markers of inflammatory reaction) are increased in patients
who develop AF (Bruins et al. 1997, Lamm et al. 2006). Corticosteroids have anti–
inflammatory activity and reduce exaggerated inflammatory reaction (Brunton et al.
2006). Prospective randomized trials in non-operative patients have reported that
corticosteroid therapy reduces the risk of recurrent and permanent AF in patients
converted from their first episode of AF (Dernellis and Panaterou 2004).
The effects of corticosteroid treatment on postoperative AF have been addressed also
in two randomized controlled trials with postoperative AF as the primary end point. The
study  by  Prasongsukarn  et  al.  studied  86  patients  scheduled  for  CABG  surgery  who
were administered 1000 mg of methylprednisolone or placebo before surgery and 4mg of
dexamethasone or placebo every 6 hours for 24 hours after surgery. The postoperative
incidence of  AF was significantly  lower  in  the  corticosteroid group than in  the  placebo
group (21% vs. 51%, respectively) (Prasongsukarn et al. 2005). Halvorsen et al.
administered 4mg of dexamethasone or placebo after induction of anesthesia and on the
first postoperative morning in 300 patients undergoing CABG surgery. They failed to
demonstrate the reducing effect of corticosteroid on the incidence of postoperative AF
(Halvorsen et al. 2003).
Two other studies deserve to be mentioned. Rubens et al. enrolled 68 patients
undergoing  CABG  and  randomized  them  to  1000  mg  intravenous  infusion  of
methylprednisolone or placebo before the surgery. Methylprednisolone was found to
have a statistically significant inhibitory effect on the incidence of postoperative AF (12%
in the treatment group vs. 34% in the placebo group) (Rubens et al. 2005). Yared et al.
studied 235 patients scheduled for CABG or valve surgery. The patients were given a
single dose of 0.6 mg/kg of dexamethasone or placebo after induction of anaesthesia.
Compared with the placebo group, the dexamethasone group had a lower incidence of
postoperative AF (19% vs. 32%, respectively) (Yared et al. 2000). However, in these trials,
postoperative AF was not a primary end point and they had no prospective definition of
AF. Thus, these studies were not primarily designed to address the effect of corticoste-
roids on postoperative AF, but on the activation of inflammatory and coagulation
pathways and recovery from cardiac surgery.
A meta-analysis analyzed the effect of perioperative corticosteroid use on the
incidence of AF after cardiac surgery. Nine studies with 990 patients were included in
the meta-analysis, and it was found that corticosteroids significantly lowered patients`
odds of developing postoperative AF by 45% (OR 0.55; 95% CI 0.39-0.78) (Baker et al.
2007). Another meta-analysis of 50 randomized controlled trials and 3323 patients
reported that corticosteroid prophylaxis reduced the risk of AF (RR 0.74;95% CI 0.63-
0.86, p<0.01) (Ho and Tan 2009).  A third meta-analysis consisting of 44 trials and 3205
patients confirmed that steroids reduced new onset AF (RR 0.71; 95% CI 0.59-0.987).
2.4.6 Statins
A few studies have reported the use of statins in relation to the development of post-
operative AF. The main limitation of these statins studies are that many of them are non–
randomized and based on different kind of registry analyses. Numerous mechanisms
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have been proposed to explain a possible protective effect of statins in the prevention of
postoperative AF after cardiac surgery including antioxidant effects, direct
antiarrhythmic effects mediated through cell membrane stabilization, protection of
ischemic myocardium, and anti–inflammatory effects (Marin et al. 2006, Patti et al. 2006,
Kostapanos et al. 2007, Chello et al. 2006, Pretorius et al. 2007). Although the precise
mechanisms by which statins  may prevent  AF have not  yet  been identified,  it  is  likely
that the effects are multifactorial.
The ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrythmia after cardiac
surgery) was the first randomized and placebo controlled trial on statin, it showed a
significant decrease in AF incidence in atorvastatin treated patients. Postoperative AF
occurred in 35 (35%) of 101 patients in the atorvastatin group vs. 56 (57%) of 99 patients
in the placebo group. Also the postoperative hospital stay was significantly lower in the
atorvastatin group compared with placebo group (6.3±1.2 vs 6.9 ±1.4 days) (Patti et al
.2006).
In an observational study of 362 patients (267 on and 95 not on statin medication) the
postoperative AF was less frequent and its duration was shorter in the statin group
compared to the non–statin group (8.2% vs. 16.8%, respectively). One important
limitation of this study was that the recognisation of AF episodes was not based on
continuously ECG recording (Ozaydin et al. 2007). In another study of 234 patients
undergoing CABG, 28.2% experienced postoperative AF. Multivariante analysis found
that the risk of postoperative AF was decreased with statin use (OR 0.52; 95% CI 0.28-
0.96, p<0.01). However, there were some remarkable limitations of this study; it was
retrospective, included patients with previous history of AF and various statin regiments
were used and also the study population was too small to conclude the exact effect of
statins in the prevention of AF after cardiac surgery (Marinet al. 2006). A retrospective
analysis on statins and postoperative AF among patients receiving amiodarone and beta
blocker therapy prophylactically showed that adjunctive statin pre–treatment decreased
postoperative AF by 40% (Lertsburaba et al. 2008). Mariscalco and colleagues studied 405
patients undergoing isolated CABG procedures. Postoperative AF occurred in 29.5% of
the patients with preoperative statin therapy compared with 40.9% of those patients
without statin use (p=0.017). Overall, preoperative statin use was associated with a 42%
reduction in the risk of postoperative AF (Mariscalco et al. 2007).
Nonetheless, there are also negative studies showing minimal or no benefit of statins
in the prevention of postoperative AF. Vrani et al. studied a total of 2096 patients
undergoing  cardiac  surgery,  including  isolated  valve  surgery  and  patients  with  low
ejection fraction. AF occurred in 31.4% in both the statin and non–statin groups.
However, this study was retrospective, patients having received different doses of
several  statins,  and  also  the  data  concerning  duration  of  statin  use  prior  to  cardiac
surgery were incomplete (Vrani et al. 2008).
2.4.7 Other medical therapy
Digoxin has not been found effective in the prevention of postoperative AF (Andrews
et al. 1991, Kowey et al. 1992, Tyras et al. 1979). Verapamil also seems to be ineffective
(Andrews et al. 1991). Intravenous diltiazem has been compared with intravenous nitrate
in the prevention of AF in four different studies (Hannes et al. 1993, Seitelberger et al.
1994, El–Sadek and Krause 1994, Malhotra et al. 1997). In these studies diltiazem turned
out to be more effective than nitrates. On the other hand, no placebo–controlled trials
with diltiazem have been carried out. According to a meta-analysis by Wijeysundera et
al., diltiazem has no significant effect on supraventricular tachycardias (SVT) after
cardiac surgery (OR 0.73) 95% CI 0.48–1.12. A subgroup analysis in a meta–analysis of
calcium channel blockers found that non–dihydropyrinines significantly suppressed
post–surgery supraventricular arrhythmias (OR 0.62. 95% CI 0.41–0.93), but with a high
heterogeneity (Wijeysundera et al. 2003). In one randomized controlled trial
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triiodothyronine was found to decrease postoperative AF in patients who had a low left
ventricular ejection fraction (Klemperer et al.1996).
Anglade et al. demonstrated that the preoperative use of thiazolidinediodine, which
has some anti-inflammatory properties in diabetic patients undergoing cardiac surgery,
was associated with a 20% reduction in postoperative AF, but it did not reach statistical
significance due to the study being underpowered (Anglade et al. 2007).
A large prospective observational study of 4657 patients undergoing cardiac surgery
demonstrated that postoperative use of angiotensin-converting enzyme inhibitor (ACEI)
reduced the incidence of postoperative AF after cardiac surgery (OR, 0.62; 95% CI, 0.48-
0.79) (Matthew et al. 2004). Negative studies about the preventive effect of ACEIs and
angiotensin receptor blockers (ARB) on postoperative AF have also been published.
Coleman and colleagues performed a single center, retrospective study of 1469 matched
patients undergoing cardiac surgery. They found that postoperative ACE inhibitor use
was not associated with a reduction of postoperative AF after cardiac surgery (OR 0.95;
95% CI 0.57-1.56) (Coleman et al. 2007). Similarly, data extracted from two randomized
controlled  trials  (AFIST  II  and  AFIST  III)   showed  that  preoperative  use  of  ACE
inhibitors or ARB was not associated with a significant reduction in  postoperative AF
(OR 0.71; 95% CI 0.42-1.20) (White et al. 2007).
In a prospective trial with 160 patients, the efficacy of preoperative and postoperative
treatment of n-3 polyunsaturated fatty acid (PUFA) were assessed. The incidence of
postoperative AF was lower in the PUFA group than in the control group (15% vs. 33%,
respectively, p = 0.013) (Calo et al. 2005). The effect of a new antiarrhythmic agent,
dronedarone, has not been assessed in the prevention of AF after cardiac surgery. The
efficacy of omega-3 fatty acids for the prevention of recurrent AF has been studied in
non-operative patients, but not in the prevention of AF after cardiac surgery (Kowey et
al. 2010).
2.4.8 Atrial pacing
The effectiviness of atrial pacing in the prevention of AF occurring after cardiac sur-
gery has been investigated in many studies. Gerstenfeld et al. demonstrated that biatrial
and right atrial pacing were well tolerated and safe (Gerstenfeld et al.1999). In another
study they found that biatrial pacing combined with beta blockers decreased the
incidence of postoperative AF. Patients older than 70 years especially seemed to benefit
from the combination treatment (Gerstenfeld et al. 2001). In a randomized trial of 154
patients, dynamic right, left and biatrial pacing decreased the incidence of AF compared
with the control group (Greenberg et al. 2000). Correspondingly, in another study
dynamic right atrial overpacing decreased postoperative AF after cardiac surgery
(Blommaert et al. 2000). In a study comparing the location of atrial pacing, biatrial pacing
was more effective than right or left atrial pacing (Fan et al. 2000). The effectiviness of
biatrial pacing in the prevention of postoperative AF has also been reported by Levy et
al. (Levy et al. 2000). In their prospective study with 118 patients, biatrial pacing but not
right or left atrial pacing decreased the incidence of postoperative AF (Daoud et al. 2000).
In a randomized trial of 100 patients, AAI pacing (pacing cut-off 10 beats above the
normal pulse rate) was compared with no pacing. No difference was found between the
groups. Instead, more atrial premature contractions were found in the pacing group
(Chung et al. 2000). In another study by Kurz et al., biatrial pacing was compared with
pharmacological treatment in the prevention of atrial fibrillation. The trial was
terminated early because of proarrhytmias in the pacing group (Kurz et al.1999). In a
study by Hakala et al., dynamic right atrial overpacing or prevention of bradycardia did
not decrease the incidence of postoperative AF (Hakala et al. 2005).
Two meta-analyses have investigated the effect of pacing on AF incidence after
cardiac surgery. In a meta-analysis by Chrystall et al., 10 studies and 1473 patients, three
different methods of atrial pacing (right, left and biatrial) were compared. Only biatrial
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pacing was shown to decrease the incidence of postoperative atrial AF (Crystal et al.
2002). Similiarly, another meta-analysis by Burgesset et al. showed that only biatrial
pacing had a significant effect in reducing the incidence of AF from an average of 35.3%
in the control group to 17.17% in the paced group (OR 0.44, 95% CI 0.31–0.64) (Burgess et
al. 2006).
2.4.9 Posterior pericardiotomy
The concept of opening the posterior pericardium to prevent atrial fibrillation is based
on the assumption that this would decrease the accumulation of pericardial fluid
postoperatively. The posterior pericardium is usually opened with a 4 cm longitudinal
incision. Mulay and colleagues were the first to report the effectiviness of this procedure
in the prevention of postoperative AF (Mulay et al. 1995). They found that the occurrence
of a significant accumulation of pericardial fluid on echocardiogram decreased from 40%
in the control group to 8% in the intervention group. At the same time, the incidence of
supraventricular tachyarrhythmias decreased from 36% to 8%. Two other randomized
trials have also found that posterior pericardiotomy decreases the incidence of
postoperative AF (Farsak et al. 2002, Kuralay et al. 1999).
In contrast, in a prospective, controlled trial of 100 patients, posterior pericardiotomy
had no effect on postoperative atrial fibrillation (Asimakopoulos et al. 1997). Thus, the
role of posterior pericardiotomy in the prevention of AF remains unclear.
2.4.10 Other possible useful strategies
Oxidative stress has been suggested to have a role in the pathogenesis of AF, and
some trials have tested  antioxidative agents for the prevention of postoperative AF after
cardiac  surgery.  Ozaydin  et  al.  studied  in  their  prospective,  randomized,  double  blind
and placebo controlled study with 115 patients the effect of N-Acetylcysteine on
postoperative  AF.  The  incidence  of  AF  was  significantly  lower  in  the  treatment  group
than in the placebo group (Ozaydin et al. 2008).
In another study Carnes et al. tested the hypothesis that perioperative oxidative stress
has a significant role in the etiology of AF. Of the patients treated with ascorbate, 16.3%
developed AF or flutter, compared with 34.9% in the control group,  the difference
beeing statistically significant (Carnes et al. 2001).
The American College of Chest Physicians guidelines also recommend mild hypo-
thermia, the use of posterior pericardiotomy and heparin-coated CPB circuits as possible
intraoperative preventive strategies for the reduction of AF following cardiac surgery
(Creswell et al. 2005). However, robust evidence for these strategies is more limited.
2.4.11 Comparison of different prevention modalities
A number of studies of the prevention of AF after heart surgery have been published.
However, not many of them have compared different prophylaxis methods.
In a prospective, randomised, double-blind and placebo-controlled study, 253 patients
were randomized to receive orally administered amiodarone and metoprolol, only
metoprolol and only sotalolol or only placebo. In patients receiving the combination
medication (amiodarone + metoprolol) and patients receiving sotalolol, the occurrence of
atrial fibrillation decreased from 53.8% in the placebo group to 30.2% and 31.7%,
whereas in the metoprolol group its occurrence was 40.3%. Treatment effects did not
differ significantly between the active drug groups (Auer et al. 2004).
Cardona and colleagues, in turn, compared right atrial pacing, intravenously
administered amiodarone and orally administered beta-blocker medication with regard
to preventing atrial fibrillation after heart surgery and the duration of hospital stay.
However, the sample size was too small for any conclusions to be drawn from their
results (Cardona et al. 2003).
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Wurdeman et al. compared in their meta-analysis the effectiviness of amiodarone and
sotalol  in  the  prevention  of  AF  after  cardiac  surgery.  Ten  randomized  and  controlled
trials with 1303 patients were included in the meta-analysis. Both amiodarone and
sotalol were more effective than placebo treatment in the prevention postroperative AF.
There were no differences between amiodarone and sotalol (sotalol -21.5%; 95% CI -28.3
to -14.6, and amiodarone -14.1; CI -20.1 to -8.1) (Wurdeman et al. 2002).
,Iin their meta-analysis Zimmer and colleagues studied 13 trials and 1783 patients. In
this meta-analysis the efficacy of amiodarone, sotalol, pacing and amiodarone were
compared. They did not find any difference between these treatment modalities as
regards the efficacy of AF prophylaxis (Zimmer et al. 2003).
In another meta-analysis by Crystal et al., 52 randomized trials of beta-blockers,
sotalol, amiodarone or pacing were studied in the prevention of AF after cardiac surgery.
Each  of  the  three  drug  treatments  were  effective  in  the  prevention  of  AF,  with  the
following odds ratios: sotalol, 0.35 (95% CI 0.26–0.49), beta-blockers, 0.39 (95% CI 0.28–
0.52) and amiodarone, 0.48 (95% CI 0.37–0.61). Pacing was also effective: for biatrial
pacing the OR was 0.46 (95% CI 0.30–0.71). They concluded that beta-blockers,
amiodarone and sotalol all reduced the risk of postoperative AF after cardiac surgery,
with no marked difference between them (Crystal et al. 2002).
In their meta-analysis Burggess et al. analyzed 94 trials using beta-blockers, sotalol,
amiodarone, magnesium, overdrive pacing, digoxin, and calcium channel blockers in the
prevention of AF after cardiac surgery. Amiodarone, sotalol, beta-blockers, magnesium
and atrial pacing were effective in the prevention of AF after cardiac surgery. However,
they concluded that the effect of beta-blockers is less than previously thought (Burgess et
al. 2006).
2.4.12 Impact of prevention on outcome after cardiac surgery
Beta-blockers, sotalol, amiodarone, bi-atrial pacing and magnesium are effective in the
prevention of AF after cardiac surgery. In a meta-analysis of 52 prospective randomized
trials, the preventive strategy of AF reduced the length of hospital stay by somewhat less
than half a day: conventional beta-blockers or sotalol did not significantly reduce the
length of hospital stay. Amiodarone reduced the length of hospital stay significantly by
0.91 days. The incidence of stroke was not reduced by AF prophylaxis in this meta-
analysis (Crystal et al. 2002). Another meta-analysis comparing AF prophylaxis
(amiodarone, sotalol, pacing and procainamide) with placebo involved 13 trials and 1783
patients. The results revealed a decrease in the length of hospital stay by 1.0 ± 0.2 days
with the various modalities of antiarrhythmic prophylaxis. However, there was no
significant reduction in the cost of the treatment. In addition, the maintenance of sinus
rhythm did not decrease the incidence of stroke (Zimmer et al. 2003).
A recently published meta-analysis of 49 prospective randomized trials assessed the
efficacy of conventional beta-blockers, amiodarone, sotalol, magnesium and atrial pacing
in the prevention of AF after cardiac surgery. Only amiodarone and atrial pacing
significantly reduced the length of hospital stay (-0.60 days, 95% CI -0.92 to -0.29, and -
1.3 days, 95% CI -2.55 to -0.08, respectively). Collectively, all treatments analysed
together also reduced the incidence of stroke (OR 0.63, 95% CI 0.41-0.98). Amiodarone
was the only intervention that alone reduced the risk of stroke (OR 0.54, 95% CI 0.30-
0.95) (Burgess et al. 2006).
2.5 TREATMENT OF ATRIAL FIBRILLATION AFTER CARDIAC SURGERY
Spontaneous conversion of AF to sinus rhythm (SR) after cardiac surgery is common.
Altogether 15% of patients converted to SR within two hours (VanderLugt et al. 1999)
and 80% within 24 hours (Cochrane et al. 1994) when either placebo or digoxin was
given.
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Two management strategies are available to treat AF after CABG: rate control and
rhythm control. In addition, anticoagulant therapy is used to reduce the risk of embolic
complications (Ommen et al. 1997). There are no specific guidelines about when
anticoagulant therapy should be started in patients who develop AF after CABG. Two
reviews recommend anticoagulant therapy with heparin and warfarin if AF persist for
more than either 24 hours (Ommen et al. 1997) or 48 hours (Maisel et al. 2001). The
American College of Cardiology, the American Heart Association and the European
Society of Cardiology have published joint guidelines for the management of patients
with AF (Camm et al. 2010). The guidelines recommend managing patients with
postoperative AF in a similar fashion to AF in non-surgical patients. They recommend
the use of anticoagulant treatment with heparin or warfarin with a target INR 2.0–3.0 in
high risk patients if AF persist more than 48 hours. In addition, in higher risk patients,
even if sinus rhythm returns, warfarin should be continued for 4 weeks as there is a
delay in the return of atrial contractility after a period of AF (Daoud et al. 2004).
Initial managements includes the correction of predisposing factors (such as pain
management, haemodynamic optimization, weaning of i.v. inotropes, correcting
electrolytes and metabolic abnormalities, and addressing anaemia or hypoxia) where
possible (Camm et al. 2010). Beta blockers are considered to be the first-line therapy for
rate control when ventricular response is rapid (Andrews et al. 1991). Digoxin slows
down the ventricular response at rest, but seldom adequately when sympathetic tone is
high. When beta blockers alone inadequately control the heart rate, calcium channel
blockers may be administered to achieve adequate rate control (Maisel et al. 2001).
Infusion of amiodarone can also be used for rate control of AF (Cochrane et al. 1994).
Early electrical cardioversion may be necessary in hemodynamically compromised
patients. Unfortunately, AF tends to relapse after cardioversion (Ommen et al. 1997,
Camm et al. 2010). Reports on the use of various antiarrhythmic drugs to restore SR in
patients with AF after CABG show diverse results. This is partly due to the spontaneous
restoration of SR. Some of the drugs (dofetilide, procainamidi, intravenous quinidine)
are not available in many countries, including Finland. When antiarrhythmic therapy is
indicated, drug-induced proarrhythmia should be avoided. Patients with a history of
myocardial infarction, reduced ejection fraction, or high age are at a particularly high
risk for proarrhythmias (Friedman and Stevenson 1998).
The efficacy of flecainide, a class IC antiarrhythmic agent for converting AF to SR after
cardiac surgery, has been shown (Cavaghan et al. 1988, Wafa et al. 1989). Since flecainide
increases  mortality  after  myocardial  infarction,  this  drug  should  not  be  the  first  choice
for long-term oral therapy in patients with postoperative AF (Ommen et al. 1997).
Another drug with class III antiarrhythmic properties, sotalol, led to conversion to SR in
85% of patients in 12 hours (Campbell et al. 1985). Ibutilide, a class III antiarrhythmic
agent, given intravenously converted 44% of AF patients to SR after cardiac surgery,
compared with 15% of patients who were given placebo, but ibutilide infusion was
associated with an up to 3% risk of torsades de pointes proarrhythmia (Vander Lugt et
al. 1999). Less than 10% of patients with postoperative AF after CABG who are
discharged in sinus rhythm will have recurrent AF in six weeks after discharge, and
prophylactic treatment with calcium-channel blockers, quinine, or amiodarone after
discharge does not reduce the rate of recurrence (Yilmaz et al. 1996).
Intravenous amiodarone therapy converts AF to SR within 12 to 24 hours in 40% to
90% of patients, and amiodarone therapy provides effective rate control (McAlister et al.
1990, Cochrane et al. 1994).
In the prospective, randomized and placebo-controlled trial by Kowey et al.,
vernakalant was effective in treating patients with postoperative AF after cardiac
surgery. Vernakalant converted AF to sinus rhythm in 47 of 100 patients, compared with
7 of 50 patients in the placebo group (Kowey et al. Circulation 2009).
Overall, although many antiarrhythmic options are available to convert AF to SR after
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CABG, the combination of reasonable efficacy and low risk of proarrhythmia favours
amiodarone as the drug of choice for patients requiring antiarrhythmic drug treatment
(Ommen et al. 1997).
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3 AIMS OF THE PRESENT STUDY
The  overall  aim  of  this  study  was  to  evaluate  different  pharmacological  methods  in
the prevention of AF after cardiac surgery.
The specific aims were:
1. To test whether intravenous metoprolol after cardiac surgery is more effective than
oral metoprolol in the prevention of AF.
2. To test whether intravenous corticosteroid administration is effective in the pre-
vention of  AF after cardiac surgery.
3. To compare the efficacy of intravenous metoprolol and intravenous amiodarone in
the prevention of AF after cardiac surgery.
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4 PATIENTS AND METHODS
4.1 PATIENTS
4.1.1 Study I
This study took place at Kuopio University Hospital. From September 2004 to August
2005, 240 consecutive patients who were scheduled to undergo their first on-pump
CABG, aortic valve replacement or combined aortic valve replacement and CABG were
enrolled in the study. The exclusion criteria were previous episodes of AF or flutter, sick
sinus syndrome, II- or III-degree atrioventricular block and uncontrolled heart failure.
Patients were also excluded if they had had AF before the first postoperative morning
and if they had to stay in the intensive care unit beyond the first postoperative day.
Patients were also excluded if the systolic pressure was < 100mmHg, if the pulse rate was
< 60 beats per minute (bpm) at the time of randomization, or if temporary pacing was not
functioning properly, when tested before randomization. The reasons for exclusion and
numbers of enrolled patients who were excluded before randomization were as follows:
experiencing AF before first postoperative morning (three patients), staying in the
intensive care unit longer than one day (18 patients), pulse rate <60 bpm (12 patients),
systolic pressure less than 100 mmHg (17 patients), inaccurate function of temporary
pacemaker (11 patients), new II- or III-degree atrioventricular block (15 patients),
operation was unexpectedly performed off-pump (seven patients), mitral valve repair
(two patients), and  replacement of ascending aorta (two patients). Also, two patients
died before the first postoperative morning. The study protocol was approved by the
local ethics committee, and all patients gave informed consent.
4.1.2 Study II
The study took place at Kuopio University Hospital, Oulu University Hospital and
Tampere University Hospital. From August 2005 to December 2006, 241 consecutive
patients scheduled to undergo their first on-pump CABG, aortic valve replacement or
combined aortic valve replacement and CABG were enrolled in the study. The exclusion
criteria were previous episodes of AF or flutter, uncontrolled diabetes mellitus, systemic
bacterial or mycotic infection, active tuberculosis, Cushing’s syndrome, psychotic mental
disorder, Herpes Simplex keratitis or renal insufficiency (serum creatinine exceeding 200
μg/ml). Patients were also excluded if they had a history of previous peptic ulcer or
thrombophlebitis. Altogether 650 eligible CABG, AVR of combined CABG+AVR were
screened  for  the  study.  The  most  common  reason  for  exclusion  was  that  the  operation
was performed off-pump. The study flow diagram is presented in Figure 1. The study
protocol was approved by the Kuopio University ethical committee, and all patients
gave informed consent.
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Figure 1.  Flow diagram of the study
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4.1.3 Study III
The study took place in three cardiac centres in Finland: Kuopio University Hospital,
Tampere Heart Centre and Vaasa Central Hospital. The study enrolment occurred from
August 2006 to January 2009. We enrolled 316 consecutive patients to undergo their first on-
pump CABG surgery, aortic valve replacement, or combined CABG and aortic valve surgery.
Patients  with  previous  episodes  of  AF  or  flutter,  sick  sinus  syndrome,  2nd or  3rd degree AV
block,  severe  asthma  or  chronic  obstructive  pulmonary  disease,  thyroid  dysfunction  and
allergy  to  iodine  were  excluded.  Patients  were  also  excluded  if  they  stayed  longer  than  24
hour in the intensive care unit, if AF occurred before the randomization, if they refused to
participate, if temporary pacing was not functioning properly, and if patients had ongoing
medication with tioridatsine, erythromycin, pentamidine, terfenadine, sisapridine or
corticosteroids. The most common reason for exclusion was the inaccurate function of
temporary pacing before the randomization. The study flow diagram is presented in Figure
2. The study protocol was approved by the Kuopio University ethical committee, and all
patients gave informed consent.
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Figure 2. Flow diagram of study
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4.2 DESCRIPTION OF PROCEDURES
4.2.1 Operative techniques
All patients underwent on-pump cardiac surgery with standard cardiopulmonary bypass.
Intermittent blood or cold crystalloid cardioplegia solution were administered via the
antegrade or retrograde route. The cardioplegia solution consisted of magnesium 16mmol/l,
and no extra magnesium substitution was given. Cardiopulmonary bypass with moderate
systemic hypothermia (venous blood temperature 32oC) and moderate haemodilution
(hematocrite 0.22) was used with flow rates of 2.2-2.4 l/m2 and mean perfusion pressure of
50-85 mm Hg. Epicardial temporary pacing wires were applied for every patient.
4.2.2 Postoperative follow up
After the operation, patients were followed in the intensive care unit and were weaned off
the ventilator when they fulfilled the following criteria: haemodynamic stability, peripheral
temperature more than 32oC, co-operativity, and no major bleeding. Chest drains were
removed on the first postoperative day and the patients were moved to the surgical ward.
All  the  patients  were  connected  to  three-channel  ward  monitors  for  continuous  ECG
monitoring  for  the  whole  study  period.  The  ward  monitor  stored  the  ECG  recordings  for
subsequent analysis. A 12-lead ECG recording was done if necessary to confirm the rhythm.
The endpoint of the study was the occurrence of the first AF episodes or the completion of
the study protocol. After the first episode of AF, the study protocol was discontinued.
4.3 STUDY SETTINGS
4.3.1 Study I
The  study  period  started  on  the  first  postoperative  morning,  when  randomization  was
performed. Treatment allocations were sealed in numbered envelopes in a blinded
randomized manner. Each enrolled subject was assigned either to the intravenous group or
oral group according to the allocation designated in the next envelope opened in sequence.
Patients in the intravenous group were given metoprolol according to the heart rate as
follows: when heart rate was 60-70 bpm, the metoprolol dose was 1 mg/h; when heart rate
was 70-80 bpm, the dose was 2 mg/h; and when the heart rate was > 80 bpm, the dose was 3
mg/h. If heart rate dropped < 60 bpm or systolic blood pressure dropped < 100 mmHg during
treatment, intravenous metoprolol was discontinued for one hour and then continued
according to heart rate, as described above. Patients in the oral metoprolol group were given
metoprolol according to heart rate as follows: when heart rate was 60-70 bpm, the metoprolol
dose was 25 mg three times a day; when heart rate was 70-80 bpm, the dose was 50 mg two
times a day; and when heart rate was over 80 bpm, the dose was 50 mg three times a day.
The study period was 48 hours for both groups.
The endpoint of the study was the occurrence of the first AF episode or the completion of
the 48 hours protocol. After the first episode of AF, the study protocol was discontinued.
The sample size was determined on the assumption that the incidence of AF could be
reduced from 30% in the oral metoprolol treatment group to 15% in the intravenous
metoprolol treatment group. At a level of =0.05 with a power greater than 0.80, the sample
size was calculated to be 121 patients in each group.
4.3.2 Study II
The study period started immediately after the operation was performed. Randomization
was performed on the operation day by a biostatistician. The groups were block-randomized
with block sizes of six, separately in each hospital. Randomization lists were sent to the
hospital pharmacy, where the study drugs were prepared. The investigator sent the name
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and date of birth by telefax to the pharmacy each time a new patient had given informed
consent. The pharmacy personnel selected the next number on the randomization list,
labelled the drug container with the patient’s name, and sent the container to the department
where the patient was treated. The study group remained blinded to the patient and the
doctors. The randomization codes were opened after the end of the study. It was not
necessary to break the code for any of the patients, so blinding was assured.
The study drugs were prepared in the hospital pharmacy. Solutions were prepared using
aseptic techniques under a laminar flow hood. Reconstituted solutions of hydrocortisone
sodium succinate (Solu-Cortef) in 0.9% sodium chloride solution (Natriumklorid Braun 9
mg/ml) were prepared by transferring 100 mg/2ml hydrocortisone sodium succinate into
polyethylene infusion containers containing 100 ml of 0.9% sodium chloride solution.
Placebo  solutions  were  prepared  by  transferring  2  ml  0.9%  sodium  chloride  solution
(Natriumchlorid Braun 9 mg/ml) into polyethylene infusion containers containing 100 ml of
0.9% sodium chloride solution. Both the active drug and the placebo preparations were
identical as regards color and other characteristics.
Each patient was administered either hydrocortisone or placebo as follows: the first dose
in the evening of the operative day, and then one dose every eight hours during the next
three days. In addition, all patients were given oral metoprolol according to heart rate as
follows: when the heart rate was 60-70 beats per minute (bpm), the metoprolol dose was 25
mg two times a day; when heart rate was 70-80 bpm, the dose was 50 mg two times a day;
and when it was over 80 bpm the dose was 50 mg three times a day. The study period was 84
hours in both groups.
The endpoint of the study was the occurrence of the first AF episode or completion of the
84 hours study period. All patients in the hydrocortisone and placebo groups had complete
courses until the designated endpoints, so intention-to-treat was the same as actual
treatment. After the first AF episode, the study protocol was discontinued. Investigators
phoned the patients 2-4 weeks after the operation. If the patient reported that he or she had
had contact with a physician due to suspected infection, patient charts were ordered to verify
and check the event. In addition, the patient charts were checked 6 months after the
operation to assess the incidence of major postoperative complications (mediastinitis or other
complications requiring hospitalisation).
The sample size determination was based on the assumption that the incidence of AF can
be diminished from 30% to 15% with intravenous hydrocortisone treatment. At a level of
=0.05 with a power greater than 0.80, the sample size was 120 patients in each group.
We also performed a meta-analysis of randomized controlled trials of corticosteroid
therapy in the prevention of postoperative atrial fibrillation after cardiac surgery. We
selected the trials from the PubMed database. The selection criteria were: a randomized,
placebo-controlled trial; the primary outcome was AF, and the incidence of AF was reported
either  in  percentages  or  in  numbers  together  with  the  total  number  of  patients  in  the
treatment and placebo groups. We found four studies that fulfilled these criteria
(Prasongsukarn et al. 2005, Rubens et al. 2005, Halvorsen et al. 2003 and Yared et al. 2000).  In
a more thorough examination we discerned that two studies did not have defined AF as a
primary outcome (Rubens et al. 2005, Yared et al. 2003) and these studies were excluded from
the meta-analysis.  Finally, two studies (Prasongsukarn et al. 2005, Halvorsen et al. 2003)
remained in the meta-analysis together with the present study.
4.3.3 Study III
The study perioid started on the first postoperative morning, when the randomization was
performed. Treatment allocations were sealed in numbered envelopes in a blinded
randomized manner. Each enrolled subject was assigned to the intravenous metoprolol or
intravenous amiodarone groups according to the allocation designated in the next envelope
opened in sequence.
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Patients in the intravenous metoprolol group were given metoprolol according to the
heart rate as follows: when the heart rate was 60-70 bpm, the metoprolol dose was 1mg/h; at
heart rate 70-80 bpm, the dose was 2mg/h; and at heart rate >80 bpm, the dose was 3mg/h. If
the heart rate dropped < 60 bpm or systolic blood pressure dropped < 100 mmHg during the
treatment, intravenous metoprolol administration was discontinued for one hour and then
continued according to the heart rate as described above. Patients in the intravenous
amiodarone group received amiodarone 15mg/kg, not exceeding a total dose of 1000 mg
amiodarone in 24 hours. Also in the amiodarone group, if the heart rate dropped < 60 bpm or
systolic blood pressure dropped < 100 mmHg during the treatment, intravenous amiodarone
was discontinued for one hour.
The endpoint of the study was the occurrence of the first AF episode or completion of the
48 hours  study period.  All  patients  in  the  metoprolol  and amiodarone group had complete
courses until the designated endpoints, thus intention-to- treat was the same as actual
treatment. After the first episode of AF, the study protocol was discontinued.
The study was planned as an equivalence, open-labelled study. We calculated the sample
size using the formula presented by Pocock (Pocock 1983). On the basis of previous studies,
we  assumed  an  incidence  of  AF  of  15%  in  both  groups  and  defined  equivalence  as  a
difference in the treatment effect less than 5 percentage points in both directions. As an alpha
level of 0.10 with a power greater than 80%, the sample size was calculated to be 158 patients
in each group.
4.3.4 Definitions
The rhythm was defined as AF when there were no consistent P waves before each QRS
complex and ventricular rate was irregular. AF episodes lasting longer than 5 minutes were
recognized.
Perioperative myocardial infarction was defined as the development of new Q waves. A
stroke was defined as a new neurological symptom verified by correlative changes in
computer  tomography.  A  psychotic  mental  disorder  was  defined  as  a  new  psychotic
symptom diagnosed by the psychiatrist. Mediastinitis was defined as deep sternal infection
requiring resternotomy and operative revision. Superficial infections were defined as wound
infections in the sternotomy or leg wounds which were treated without surgical intervention.
Hypotension was defined as systolic blood pressure less than 100 mmHg, and bradycardia as
heart rate less than 60 beats per minute. Resternotomy was defined as reoperation because of
bleeding. Thrombophlebitis was defined as local pain, tenderness, redness and bulging of the
vein.
4.4 STATISTICS
We analyzed the difference in continuous variables using the unpaired t-test. We tested
dependencies between the treatment grups and categorical variables using the chi-square test
for independence or, in the case of low expected frequencies, the Fisher exact test. Kaplan-
Meier  curves  were  plotted  for  the  development  of  AF  after  cardiac  surgery.  In  adition,  we
used a multivariate Cox proportional hazards model to determine the hazard ratio (HR) of
AF in the metoprolol group compared with the amiodarone group (study III) and in the
hydrocortisone  group  compared  with  the  placebo  group  (study  II).  Possible  confounders
(age, sex, left ventricular ejection fraction, type of operation, unstable angina pectoris, chronic
obstructive pulmonary disease and right coronary artery bypass) were adjusted in the model.
We verified the assumptions of the Cox proportional hazards regression analysis with log-
minus-log plots. We performed a meta-analysis of randomized controlled trials of
corticosteroid  therapy  on  the  prevention  of  postoperative  AF  after  cardiac  surgery.  We
selected the trials from the PubMed database. The selection criteria included a randomized,
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placebo controlled trial and the primary outcome was AF; the incidence of AF was reported
either  in  percentages  or  in  numbers  together  with  the  total  number  of  patients  in  the
treatment and placebo groups. We found four studies that fulfilled these criteria. In a
through examination, we discerned that two studies did not define AF as a primary outcome;
these studies were excluded from the meta-analysis. Thus, two studies remained in the meta-
analysis together with our study. We used fixed-effects tests. The three studies were
homogeneous (Heterogeneity test: Q2=4.12; p=0.3). The limit for statistical significance was a
p-value less than 0.05. All statistical procedures were performed with SPSS for Windows,
release 14.0 (SPSS, Chicago, IL, USA).
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5 RESULTS
5.1 STUDY I
A majority (174, 72.5%) of the patients were men. The mean age of the patients was 65.5 ±
9.6 years, with no differences between the groups. Neither was there any difference between
the groups as regards demographic data, comorbidities, or cardiac diseases. The preoperative
data of the patient groups are presented in Table 5.
Table 5. Demographics of the patient groups
Characteristics PO group N=121 IV group N=119 Univariate p
Age (years) 65.7±9.8 65.3±9.4 0.743
Gender: male/female (n ) 88/33 86/33 0.937
LVEF (%) 63.1±16.4 62.4±13.2 0.753
Hypertension (%) 55.0 58.0 0.642
History of COPD (%) 2.5 0.9 0.662
Diabetes mellitus (%) 24.2 21.9 0.685
CCS class (%) 0.214
I 1.7 3.4
II 26.1 26.7
III 52.9 41.4
IV 19.3 28.4
Preoperative use of -blockers (%) 91.5 84.5 0.097
History of stroke or TIA (%) 7.6 4.4 0.300
History of claudication (%) 3.4 4.4 0.685
Unstable angina pectoris (%) 24.8 26.9 0.711
Three-vessel disease (%) 82.5 83.3 0.862
Data are expressed as means (standard deviation) or percentages of patients or number of patients.
Abbreviations: CCS=Canadian Cardiac Society, COPD=chronic obstructive pulmonary disease, LVEF=left
ventricle ejection fraction, PO=per oral metoprolol, IV=intravenous metoprolol, TIA=transient ischemic
attack
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Most of the operations in both groups were isolated CABG. There were no differences
between the groups in the number of distal anastomoses. Neither was there any difference
between  the  groups  with  respect  to  pump  time,  cross-clamp  time  or  first  postoperative
creatinine kinase-MB mass. The operative data of the patient groups are presented in Table 6.
Table 6. Perioperative data of the patients
Characteristics PO group N=121 IV group N=119 Univariate p
Type of operation (%) 0.753
Isolated CABG 81.9 79.6
Isolated AVR 7.8 10.6
Combined CABG and AVR 10.3 9.7
Right coronary artery bypass (%) 77.1 79.0 0.726
Pump time (min) 92.4±42.3 93.2±36.8 0.875
Cross-clamp time (min) 83.4±49.3 79.5±31.6 0.500
Number of peripheral anastomoses (n) 3.7±1.1 3.9±1.1 0.336
First post-operative CK-MBm (g/l) 23.8±11.1 25.2±13.3 0.408
Data are expressed as means (standard deviation) or percentages of patients. Abbreviations:
AVR=aortic valve replacement, CABG=coronary artery bypass grafting, CK-MBm=creatinine
kinase-MB mass, PO=per oral metoprolol, IV=intravenous metoprolol
The incidence of postoperative AF was significantly lower in the intravenous group than
in the oral group (16.8% vs 28.1%). The absolute difference in the incidence of AF was 11.3%
and the number needed to treat (NNT) to prevent one AF was 8.8.   In addition, the time of
AF from the start of the metoprolol medication to the first AF episode was slightly longer in
the intravenous group than in the oral group (30.1 h ± 10.1 h vs. 26.5 h ± 11.8 h, p=0.08). The
serum potassium concentration at the time of AF did not differ between the groups.
Intravenous metoprolol administration was discontinued for one hour in 18/119 patients
(15.1%). The reasons for this were a drop in systolic blood pressure below 100 mmHg in
14/119 (11.8%) patients, and a drop in heart rate below 60 bpm in 4/119 (3.4%) patients.
There was no mortality in the study groups during the study period, but one patient in the
intravenous group died on the fourth postoperative day due to myocardial infarction. The
incidence of postoperative stroke, conduction disturbances, postoperative mediastinitis,
perioperative myocardial infarction or resternotomy due to bleeding did not differ between
the groups. The postoperative data of the patients groups are presented in Table 7.
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Table 7. Postoperative data of the patients
Characteristics PO group N=121 IV group N=119 Univariate p
Atrial fibrillation (%) 28.1 16.8 0.036
Onset of AF (hours after operation) 26.5 ± 11.8 30.1 ± 10.1 0.083
Resternotomy due to bleeding (%) 2.5 0.8 0.622
Serum-potassium prior to AF (mmol/l) 4.3 ± 0.37 4.27 ± 0.36 0.782
Stroke (%) - - -
Conduction disturbances (%) 5.0 7.6 0.437
Perioperative MI - 2.5 0.120
Postoperative mediastinitis (%) - - -
Data are expressed as means. Abbreviations: AF=atrial fibrillation, PO= per oral metoprolol,
IV= intravenous metoprolol MI=myocardial infraction
5.2 STUDY II
The age of the patients (66.1 ± 9.5, 64.4 ± 8.5) did not differ significantly between the
groups. Most of the patients were men. There were no significant differences between the
groups concerning left ventricle ejection fraction, presence of comorbidities or preoperative
beta-blocker use. The preoperative data of the patient groups are presented in Table 8.
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Table 8. Demographics of the patient groups
Characteristics Placebon=121 Hydrocortisone n=120 Univariate p
Age (years) 66.1 (9.5) 64.4 (8.4) 0.16
Male gender 89 (73.6) 96 (80.0) 0.24
LVEF (%) 61.4 (11.3) 60.3 (13.1) 0.59
Hypertension 82 (67.8) 70 (58.3) 0.13
Smoking 19 (15.7) 19 (15.8) 0.98
History of COPD 3 (2.5) 4 (3.3) 0.72
BMI (kg/m2)
27.7 (4.0) 27.9 (4.0) 0.72
Diabetes mellitus 35 (28.9) 26 (21.7) 0.19
CCS class 0.53
I 1 (0.8) 2 (1.7)
II 46 (38.3) 39 (32.5)
III 52 (43.3) 62 (51.7)
IV 21 (17.5) 17 (14.2)
Preoperative use of -
blockers
103 (86.6) 99 (82.5) 0.39
History of stroke or TIA 7 (5.8) 9 (7.5) 0.59
History of claudication 6 (5.0) 4 (3.3) 0.75
Unstable angina
pectoris
27 (22.3) 20 (16.7) 0.27
Three-vessel disease 90 (75.0) 85 (71.4) 0.53
Data are expressed as means (standard deviation) or absolute numbers (%). Abbreviations:
CCS = Canadian Cardiovascular Society; COPD = chronic obstructive pulmonary disease; BMI
= body mass index; LVEF = left ventricle ejection fraction; TIA = transient ischemic attack.
Most of the operations in both groups were isolated CABG. There was no statistically
significant difference between the groups in the number of distal anastomoses. Neither were
there any differences between the groups with respect to pump time, cross clamp time, right
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coronary artery bypass, type of operation, or first postoperative creatinine kinase-muscle
brain mass. The perioperative data of the patient groups are presented in Table 9.
Table 9. Perioperative data of the patient groups
Characteristics Placebo n=121 Hydrocortisone n=120 Univariate p
Type of operation 0.49
Isolated CABG 96 (79.3) 100 (83.3)
Isolated AVR 17 (14.0) 11 (9.2)
Combined CABG and AVR 8 (6.6) 9 (7.5)
Right coronary artery bypass 87 (71.9) 77 (64.2) 0.20
Pump time (min) 93.0 (37.2) 97.9 (41.4) 0.33
Cross-clamp time (min) 77.6 (31.1) 80.0 (31.7) 0.55
N of peripheral anastomoses (n) 3.4 (1.7) 3.5 (1.6) 0.60
First post-operative CK-MBm (mg/l) 24.8 (12.2) 29.2 (45.1) 0.33
Data are expressed as means (standard deviation) or absolute numbers (%).Abbreviations:
AVR = aortic valve replacement; CABC = coronary artery bypass grafting; CK-MBm =
creatinine kinase-MB mass.
The incidence of postoperative AF during the 84-hour study period was significantly
lower in the hydrocortisone group than in the placebo group (30.0% vs. 47.9%, p=0.01)
(Figure 3).  The relative and absolute risk reductions were 37.4% and 17.9%, respectively and
the number needed to treat (NNT) to prevent AF was 5.6. The unadjusted hazards ratio (HR)
from the Cox proportional hazards model was 0.54 (95% CI 0.36–0.82). A multivariate Cox
proportional hazards model with the most important predictors of postoperative AF
ascertained the differences between the study groups (HR=0.54, 95% CI 0.35–0.83). The
incidence of in-hospital AF was also significantly lower in the hydrocortisone group than in
the placebo group (35.6% vs 51.7%, p=0.01). The concentrations of C-reactive protein on the
1st, 2nd and 3rd postoperative days were significantly lower in the hydrocortisone group than
in the placebo group (Table 9).
In the meta-analysis, corticosteroid therapy was associated with lower incidence of
postoperative AF (RR 0.67, 95% CI 0.537–0.845) (Figure 4).
The first  AF episode (onset  of  AF)  tended to  occur  earlier  (although nonsignificantly)  in
the hydrocortisone group than in the placebo group. The true meaning of this must be
interpreted  with  caution,  because  AF  onset  shows  a  skewed  distribution  and  very  large
standard deviations.
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One  patient  in  the  hydrocortisone  group  died  during  the  study  period  (cardiac  failure)
and  one  patient  in  the  placebo  group  died  on  the  ninth  postoperative  day  (multiorgan
failure). There were no statistically significant differences between the groups with respect to
postoperative infection, mediastinitis, stroke, myocardial infarction, conduction disturbances
or resternotomy caused by bleeding. There was no psychotic disorder in either study group.
The postoperative data of the patient groups are presented in Table 10.
Table 10. Postoperative data of the patient groups
Characteristics Placebo n=121 Hydrocortisone
n=120
Univariate p
AF (during 84-hour protocol) 58 (47.9) 36 (30.0) 0.01
Onset of AF (hours after operation) 21.3 (25.4) 16.0 (24.6) 0.10
In-hospital AF 62 (51.7) 42 (35.6) 0.01
In-hospital mortality 1 (0.83) 1 (0.83) 1.0
Mortality during study period - (-) 1 (0.83) 1.0
Resternotomy because of bleeding 3 (2.5) 5 (4.2) 0.50
Serum potassium before AF (mmol/L) 4.2 (0.35) 4.1 (0.43) 0.11
Stroke 1 (0.8) 1 (0.8) 1.00
Conduction disturbances 3 (2.5) 6 (5.0) 0.33
Perioperative MI 2 (1.7) 6 (5.0) 0.17
Postoperative mediastinitis (6 months) - - -
Superficial wound infections 17 (14.0)* 17 (14.1)* 1.0
Postoperative CRP levels
1st p.op. day 67.2 (30.9) 58.0 (26.9) 0.02
2nd p.op. day 161 (48.0) 118 (38.7) <0.001
3rd p.op.day 168 (52.2) 97.6 (43.8) <0.001
Data are expressed as means (standard deviation) or absolute numbers (%).
Abbreviations: AF = atrial fibrillation; CRP = C-reactive protein; MI = myocardial infarction
*(n = 71 in the placebo group and n =78 in the hydrocortisone group).
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Figure 3. The effect of corticosteroid treatment on the incidence of postoperative atrial fibrillation after cardiac
surgery (Kaplan-Meier analysis).
Figure 4. Meta-analysis of randomized controlled trials of corticosteroids therapy on the prevention of atrial
fibrillation after cardiac surgery.
42
5.3 STUDY III
The preoperative characteristics of the patients are shown in Table 11. The mean age of the
patients did not differ significantly between the groups. Male gender was more common in
the amiodarone group than in the metoprolol group. There were no significant differences
between the groups concerning left ventricle ejection fraction, presence of diabetes, COPD,
unstable  angina pectoris, hypertension, 3-vessel disease, Canadian Cardiovascular Society
class, history of stroke or transient ischemic attack history, use of statin medication and
history of claudication.
Most of the operations in both groups were isolated CABG (Table 11). There were no
statistically significant differences between the groups in the number of distal anastomoses.
Neither were there any differences between the groups with respect to pump time, cross
clamp time, right coronary artery bypass, type of operation, or first postoperativecreatinine
kinase-muscle brain mass.
A total of 75 patients (23.7%) had AF during the 48-hour study period. Atrial fibrillation
occurred in 38 of 159 (23.9%) patients in the metoprolol group and 39 of 157 (24.8%) patients
in the amiodarone group (p = 0.85) (Table 12, Figure 5). However, the difference between
treatments (-0.9 percentage point (90% CI -8.9 to 7 percentage points) did not satisfy  the
prespecified definition of equivalence that the treatment effect would be between -5 and 5
percentage  points.  The  HR  of  the  metoprolol  group  compared  with  the  amiodarone  group
was 0.99 (95% CI 0.63–1.56). This remained unchanged after adjustment for potential
confounders (age, sex, left ventricular ejection fraction, type of operation, unstable angina
pectoris, chronic obstructive pulmonary disease, and right coronary artery bypass) (adjusted
HR 1.09, 95% CI 0.67–1.76).
Atrial fibrillation occurred significantly earlier in patients in the metoprolol group than in
those in the amodarone group (mean time to onset of AF 21.1 hours (SD 11.3) vs. 27 hours
(SD 10.2: p = 0.020). In addition, after the study period but before hospital disharge, an
additional 28 (17.7%) patients in the metoprolol group and 26 (16.9%) patients in the
amiodarone group developed AF (p =0.85). The mean time to hospital disharge or transfer to
the  referring hospital  (after  cardiac  surgery)  was  5.6  days  (SD 3.5)  in  the  metoprolol  group
and 5.4 days (SD 2.7) in the amiodarone group (difference 0.23 day (95% CI -0.43 to 0.89
days)).
One patient in the amiodarone group died of cardiac arrest (ventricular fibrillation) 9
hours  after  the  start  of  the  infusion.  The  patient  had  had  amiodarone  infusion  without
temporary pauses untill ventricular fibrillation occurred. One patient in the metoprolol
group developed cardiac tamponade and died on the fifth postoperative day. One patient in
the metoprolol group developed AF 30 hours after the start of the infusion and had a stroke
38 hours later. One patient in the metoprolol group was readmitted to the intensive care unit
for respiratory failure during the study period.
Amiodarone caused thrombophlebitis of the infusion vein in 11 patients, whereas no
thrombophlebitis was observed in the metoprolol group. (7.0% vs. 0%; p = 0.001). The study
medication was temporarily discontinued because of hypotension more frequently in the
metoprolol group than in the amiodarone group (14.5% vs. 3.8%; p =0.001). In addition,
bradycardia occurred more often in the amiodarone group than in the metoprolol group
(10.8% vs. 5.0%; p =0.056). Episodes of hypotension and bradycardia did not result in
clinically important adverse events but were transient and asymptomatic. The infusion of
study medication could be restarted after the interruption in all patients. Resternotomy was
needed in 8 patients in the metoprolol group and 5 patients in the amiodarone group (5.0%
vs.3.2%; p =0.41). Adverse events are presented in Table 13.
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Table 11. Pre- and Perioperative Characteristics
Characteristic Metoprolol
(n = 159)
Amiodarone
(n = 157)
Preoperative
Mean age (SD), y 63.8 (9.0) 64.5 (9.3)
Male sex, n (%) 117 (73.6) 140 (89.2)
Mean LVEF (SD) 0.58 (0.11) 0.59 (0.10)
History of diabetes mellitus, n (%) 48 (30.2) 33 (21.0)
History of COPD, n (%) 5 (3.1) 2 (1.3)
Unstable angina pectoris, n (%) 43 (27.0) 41 (26.1)
Hypertension, n (%) 106 (66.7) 101 (64.3)
Three-vessel disease, n (%) 123 (77.4) 130 (82.8)
CCS class, n (%)
I 2 (1.3) 2 (1.3)
II 44 (28.0) 53 (33.8)
III 63 (40.1) 67 (42.7)
IV 47 (29.9) 35 (22.3)
Current smoker, n (%) 23 (14.5) 28 (17.8)
History of stroke or TIA, n (%) 11 (6.9) 7 (4.5)
Use of statins, n (%) 125 (85.0) 122 (83.0)
Use of ACE inhibitors, n (%) 62 (42.2) 69 (46.9)
History of claudication, n (%) 10 (6.3) 11 (7.0)
Perioperative
Mean number of distal anastomoses (SD) 4.1 (1.3) 4.0 (1.2)
Mean pump time (SD), min 94.5 (31.8) 92.8 (33.3)
Mean cross-clamp time (SD), min 80.3 (27.3) 79.7 (29.2)
Right coronary artery bypass, n (%) 133 (84.7) 128 (82.1)
Type of operation, n (%)
Isolated CABG 144 (90.6) 146 (93.0)
Isolated AVR 7 (4.5) 3 (1.9)
Combined CABG and AVR 8 (5.0) 8 (5.1)
ACE = angiotensin-converting enzyme; AVR = aortic valve replacement; CABG = coronary
artery bypass grafting; CCS = Canadian Cardiovascular Society; COPD = chronic obstructive
pulmonary disease; LVEF = left ventricle ejection fraction; TIA = transient ischemic attack
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Table 13. Adverse Events*
Adverse Event Metoprolol
(n = 159)
Amiodarone
(n = 157)
Group Difference
(95% CI), percentage
points
Death 1 (0.63) 1 (0.64) -0.008 (-1.8 to 1.7)
Patients with any
adverse events
42 (26) 41 (26) 0.30 (-9.4 to 10)
Patients with serious
adverse events
2 1 0.62 (-1.5 to 2.8)
Adverse events
Postoperative stroke 1 (0.63) – 0.63 (-0.61 to 1.9)
Perioperative MI 1 (0.63) 2 (1.3) -0.64 (-2.8 to 1.5)
Thrombophlebitis of
arm vein
– 11 (7.0) -7.0 (-11 to -3.0)
Bradycardia 8 (5.0) 17 (10.8) -5.8 (-12 to 0.16)
Hypotension 23 (14.5) 6 (3.8) 11 (4.3 to 17)
Resternotomy
because of bleeding
8 (5.0) 5 (3.2) 1.8 (-2.5 to 6.2)
New conduction
disturbances (RBBB,
LAHB, LPHB, LBBB)
3 (1.9) 2 (1.3) 0.61 (-2.1 to 3.4)
New atrioventricular
block (I–III degree)
1 (0.63) – 0.63 (-0.61 to 1.9)
MI = myocardial infarction; LAHB = left anterior hemiblock; LBBB = left bundle branch block;
LPHB = left posterior hemiblock; RBBB = right bundle branch block.
* Values are reported as numbers (percentages).
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Figure 5. Kaplan-Meier curves of the proportion of patients with postoperative atrial fibrillation after cardiac
surgery in the metoprolol and amiodarone groups
Patients at risk, n
Metoprolol 158 150 135 124 120
Amiodarone 156 154 138 126 117
The exact time of atrial fibrillation was unknown for one patient in each group
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6 DISCUSSION
6.1 PATIENTS
Three studies enrolled patients scheduled to undergo on-pump CABG, AVR or combined
CABG + AVR. The number of patients who were excluded from the study was quite high.
The reasons for exclusions were mainly related to safety aspects. To our knowledge, our
studies are the first using iv metoprolol for the prevention of AF after cardiac surgery on a
large scale. Thus, we wanted to be very careful not to cause any potential side effects to the
patients.  On  the  other  hand,  in  spite  of  high  exclusion  numbers,  the  number  of  patients  in
each study was high enough to provide a good representation of the general patient
population undergoing CABG, AVR or combined CABG + AVR.
Patients undergoing mitral valve surgery were not included in our studies. Such patients
often require temporary pacing and often develop heart block postoperatively. Therefore we
considered  that  iv.  amiodarone  and  iv.  metorolol  would  be  contraindicated  for  a  large
number of mitral valve surgery patients. In study II we did not include mitral valve patients
in order to keep the patient population as uniform with studies I and III as possible. Further
studies are warranted to determine whether iv. metoprolol or iv hydrocortisone are also
feasible in the prevention of AF after mitral valve surgery.
6.2 EVALUATION OF THE METHODS
The surgical and anaesthesiological methods used in our studies are generally accepted
and widely used. Different form of cardioplegia were used, but the type of cardioplegia does
not seem to influence the incidence of postoperative AF (Butler 1993, The warm heart
investigators 1994, Pehkonen et al. 1995).
All our studies were randomized controlled trials. Study I was a single-center trial, and
studies  II  and  III  were  multicenter  trials.  In  addition,  in  study  II  the  set  up  was  double
blinded. The sample size calculation was performed when designing the studies in order to
get an adequately powered sample size to allow clear conclusions. In addition, in study II we
performed a meta-analysis of existing randomized controlled trials. The selection criteria
included a randomized, placebo controlled trial with the primary outcome of AF.
6.3 INTRAVENOUS METOPROLOL IN THE PREVENTION OF AF AFTER CARDIAC
SURGERY
The main finding of study I was that the intravenous metoprolol was significantly more
effective  than oral  metoprolol  in  the  prevention of  AF after  cardiac  surgery.  There  were  no
differences between the study groups as regards any known preoperative or perioperative
risk factors for postoperative AF. Thus, our study groups are well comparable. Metoprolol is
absorbed over a large part of the intestine (Regardh and Johnsson 1980). Despite complete
gastrointestinal absorption, only about 50% of single oral therapeutic doses reach the
systemic circulation, because of presystemic elimination (Johsson et al. 1975, Jordo et al.
1980). The bioequivalent metoprolol dosage in the intravenous and oral groups in our study
was  the  same,  because  of  this  presystemic  elimination.  One  possible  explanation  for  our
finding is that orally administered metoprolol is not absorbed from the gastrointestinal tract
during the very first postoperative days after cardiac surgery. Diminished visceral blood
flow and gastrointestinal motility as well as the use of opioids can reduce the absorption of
metoprolol after surgery. Indeed, Valtola and colleagues demonstrated in their
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pharmacokinetics study that the bioavailability of metoprolol is markedly reduced when
administered in tablet form during the early phase after CABG (Valtola et al. 2007). One
previous study compared the efficacy and safety of intravenous and oral beta-blockers:
intravenous  esmolol  was  compared  with  oral  -blocker  in  a  pilot  study.  The  study  was
terminated when interim analysis revealed a significantly greater incidence of adverse effects
in the group receiving esmolol, and the lack of any reduction in AF incidence (Balcelyte-
Harris et al. 2002). In contrast, we found no serious adverse effects associated with
intravenous metoprolol therapy. Intravenous metoprolol had to be interrupted in 15.1% of
the patients because of a decrease in blood pressure or heart rate, but the medication could be
restarted in all patients as soon as heart rate or blood pressure had recovered.
The efficacy and safety of intravenous propranolol (Abel et al. 1983) and intravenous
timolol (White et al. 1984) have been studied earlier in the prevention of AF after cardiac
surgery. These studies concluded that both -blockers were effective in AF prophylaxis when
compared with placebo. However, a trend towards more frequent adverse effects in the
propranolol treatment group was reported (Abel et al. 1983).
The main limitation of our study is that many enrolled patients had to be excluded before
randomization. Because adverse effects associated with intravenous -blocker therapy have
been reported after cardiac surgery (Balcetyte-Harris 2002, White 1984), we excluded all
patients at risk of developing complications associated with intravenous metoprolol therapy.
For example, we excluded 11 patients because the functioning of a temporary pace maker
was not reliable at the time of randomization. However, the results of our study suggest that
this is not necessary, since none of the patients developed bradycardia requiring temporary
pacing.
We conclude that intravenous metoprolol therapy is more effective than oral metoprolol
therapy in the prevention of AF after cardiac surgery. In addition, we found that intravenous
metoprolol turned out to be feasible and well tolerated in postoperative cardiac patients.
6.4 INTRAVENOUS HYDROCORTISONE IN THE PREVENTION OF AF AFTER
CARDIAC SURGERY
We report the results of the first randomized, controlled, multi-center trial investigating
the effects of corticosteroid treatment on the incidence of postoperative AF after cardiac
surgery. We found that intravenous hydrocortisone reduced the relative risk of postoperative
AF by 37% compared with placebo in patients undergoing CABG, AVR or combined
CABG+AVR.  In addition, a meta-analysis in which randomized controlled trials including
ours were included clearly demonstrated the beneficial effect of corticosteroid treatment over
placebo. Furthermore, hydrocortisone therapy turned out to be feasible and well tolerated,
and we found no serious complications associated with corticosteroid therapy.
The effects of corticosteroid treatment of postoperative AF have been addressed earlier in
two randomized controlled trials with postoperative AF as the primary endpoint. The results
of these trials, however, are somewhat conflicting. In the study by Prasongsukarn et al., 86
patients scheduled for CABG were given 1000 mg of methylprednisolone or placebo before
surgery  and  4  mg  of  dexamethasone  or  placebo  every  six  hours  for  24  hours  after  surgery
(Prasongsukarn et al. 2005). In line with our findings, they found that the postoperative
incidence of AF was significantly lower in the steroid group than in the placebo group (21%
vs. 51%, respectively, p=0.005). Halvorsen et al. administered 4 mg of dexamethasone or
placebo after induction of anaesthesia and on the first postoperative morning in 300 patients
undergoing CABG (Halvorsen et al. 2003). The incidence of postoperative AF did not differ
between the dexamethasone (27%) and placebo group (32%).
There  are  several  possible  explanations  for  these  different  results.  In  the  study  by
Halvorsen et al. only two doses of dexaethasone were used, whereas in our study, as well as
in  the  study by Prasongsukarn et  al.,  corticosteroid treatment  was continued for  72  and 24
hours, respectively. Another possible explanation is the corticosteroid dose. It is somewhat
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difficult to make exact comparisons between the trials, because different corticosteroid
preparations were used. However, the anti-inflammatory effect was highest in the study by
Prasongsukarn et al., lowest in the study of Halvorsen et al. and in the middle range in our
study.  Another  issue  that  may  explain  some  differences  between  these  studies  is  the
relatively low incidence of postoperative AF in the placebo group of Halvorsen’s study (32%)
compared with the study by Prasongsukarn et al. (51%) and our study (48%).
In addition to these trials, there are two studies that deserve to be mentioned here. In one
study, 68 patients undergoing CABG were randomized to 1000 mg intravenous infusion of
methylprednisolone or placebo before surgery (Rubens et al. 2005). Methylprednisolone was
found to have a statistically significant inhibitory effect on the incidence of postoperative AF
(12% vs. 34%, respectively, p=0.02). In another study, 235 patients scheduled for CABG or
valve surgery were given a single dose of 0.6 mg/kg of dexamethasone or placebo after
induction of anaesthesia. Compared with the placebo group, the dexamethasone group had a
lower incidence of postoperative AF (19% vs. 32%, respectively, p=0.027) (Yared et al. 2000).
Although the results of these studies are interesting, it is difficult to compare them with those
of our study. In these trials, postoperative AF was not a primary endpoint, and probably
because  of  AF  is  not  defined  in  the  study  protocols.  These  studies  were  not  primarily
designed to address the effect of corticosteroids on postoperative AF but on the activation of
inflammatory and coagulation pathways and recovery from cardiac surgery.
Previous studies have found several predicators of AF after cardiac surgery (Crystal et al.
2002). To adjust for these confounding factors, we performed a multivariate analysis in which
independent predictors such as age, sex, left ventricular ejection fraction, type of operation,
unstable angina pectoris, COPD, and right coronary artery bypass were taken into account.
After adjustment for these, corticosteroid treatment remained a significant independent
predictor of freedom from postoperative AF.
As regards the mechanism responsible for the beneficial effects of corticosteroids on
postoperative AF, several studies have shown that the concentration of complement-C-
reactive protein complex (Bruins et al.1997), the number of white blood cells (Lamm et al.
2006) and the concentration of inflammatory cytokines (Aranki et al. 1996)—all markers of
increased inflammatory reaction concentration—are higher in patients with postoperative AF
than in patients who remain in sinus rhythm. Corticosteroids have anti-inflammatory activity
and reduce an exaggerated inflammatory reaction (Ishida et al. 2006). Thus, the anti-
inflammatory effect is most likely responsible for the reduced incidence of AF associated
with corticosteroid treatment although the causality between anti-inflammatory effects and
AF cannot be addressed with this kind of set-up. This is also supported by the finding in our
study that the concentration of C-reactive protein was significantly lower postoperatively in
the hydrocortisone than in the placebo group. This is also in line with the finding of Dernellis
and colleagues that corticosteroid therapy reduces both C-reactive protein values and the
risk of recurrent and permanent AF in non-operative patients (Dernellis et al. 2004).
Corticosteroids reduce nausea and vomiting and improve the patient’s appetite after
CABG (Prasongsukarn et al. 2005). Thus, corticosteroid therapy may improve the absorption
of per oral medication, such as beta blockers, and thereby reduce the incidence of AF.
Increased  risk  of  wound  infections  and  gastrointestinal  bleeding  (stress  ulcer)  can  be  a
concern with corticosteroid therapy (Ishida et al. 2006). In our study, no adverse effects were
related to hydrocortisone therapy. In the study by Prasongsukarn et al. no difference was
found between the steroid and placebo group in major complications, but the steroid group
had  more  minor  complications.  In  our  study,  there  were  no  more  complications  (minor  or
major)  in  the  study  group  than  in  the  placebo  group.  The  different  result  regarding
complications between these two studies may be explained by the different corticosteroid
preparations (methylprednisolone and dexamethasone vs. hydrocortisone) and different
dosages that were administered. Although in our study intravenous administration of
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hydrocortisone was well tolerated, our study was underpowered to assess the safety of
corticosteroid therapy.
A limitation of our study is that in order to keep the study population as homogeneous as
possible, patients undergoing mitral valve surgery were excluded. Thus, our results should
not be applied to this patient population.
One might argue that the incidence of postoperative AF in our study was high (48%). The
incidence of postoperative AF depends very much on the definition of an AF episode. In our
study,  AF  was  defined  as  an  AF  episode  lasting  >  5  min  regardless  of  whether  it  was
asymptomatic or required therapy. In a recent trial with an almost identical endpoint to that
in our study, a 57% incidence of postoperative AF was reported (Miller et al. 2005). In
addition,  in  another  study  (Prasongsukarn  et  al.  2005),  the  incidence  of  AF  in  the  placebo
group was 51%, which is in line with our results.
We conclude that intravenous administration of hydrocortisone is efficacious and well
tolerated in the prevention of AF after cardiac surgery. Larger trials will be needed to
confirm our findings and determine the short- and long-term safety of corticosteroids to
prevent postoperative AF and other arrhythmias.
6.5 COMPARISON OF INTRAVENOUS METOPROLOL VERSUS AMIODARONE IN
THE PREVENTION OF AF AFTER CARDIAC SURGERY
We found no difference in the occurrence of postoperative AF in patients treated with
intravenous metoprolol or amiodarone after cardiac surgery. Atrial fibrillation occurred in
23.9% and 24.8% of patients in the metoprolol and amiodarone groups, respectively.
However, the wide range of the confidence intervals does not satisfy the hypothesized
definition of equivalence (between -5 and 5 percentage points) and therefore does not allow
us to conclude that the two treatments are equally effective in preventing AF after cardiac
surgery. According to current guidelines, beta-blockers should be the first-line preventive
treatment  of  AF  in  patients  having  cardiac  surgery.  Amiodarone  should  be  reserved  for
patients in whom beta-blocker therapy fails or is contraindicated (Dunning et al. 2006).
Despite this, according to a recent survey, 19% of physicians reported using amiodarone as
the first-line prophylactic strategy for postoperative AF (Price et al. 2009). This nonadherence
to  guidelines  may  be  because  amiodarone  is  considered  to  be  the  most  potent  drug  in  the
prevention of AF (Lee et al. 2000) and data directly comparing the efficacy and safety of
intravenous beta-blockers and amiodarone in preventing postoperative AF are lacking.
Several studies (Study I, Crystal et al. 2002, Burgess et al. 2006, Andrews et al. 1991, Kowey et
al. 1991) have demonstrated the effectiveness of beta-blockers in preventing AF after cardiac
surgery. A meta-analysis of 27 prospective randomized trials and 3840 patients reported a
61% decrease in the incidence of postoperative AF with beta-blocker therapy (Crystal et al.
2002). In the largest randomized trial, oral amiodarone decreased the incidence of
postoperative AF after CABG by 39% compared with placebo (Mitchell et al. 2005). In a meta-
analysis of 18 randomized trials, amiodarone decreased the incidence of postoperative AF by
62% (Burgess et al. 2006).
Indeed, only a few studies have compared beta-blockers and amiodarone in a head-to-
head setting. In a recent report by Sleilaty and colleagues (Sleilaty et al. 2009), oral bisoprolol
and amiodarone were equally effective for the prophylaxis of AF after CABG. Auer and
coworkers (Auer et al. 2004) compared oral amiodarone plus metoprolol with oral sotalol,
oral metoprolol, and placebo in patients having cardiac surgery. The combination of
amiodarone and metoprolol reduced the incidence of AF significantly (44%) compared with
placebo, whereas no significant differences were found between the active groups. In these
trials, the study drugs were administered orally, whereas the drugs were given intravenously
in our study. The bioavailability of oral drugs is markedly reduced when administered in
oral form during the early phase after CABG (Valtola et al. 2007). Only one earlier trial
compared intravenous beta-blockers with intravenous amiodarone. Solomon and colleagues
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(Solomon et al. 2001) randomly assigned patients to either intravenous amiodarone for 48
hours followed by oral amiodarone until discharge, or intravenous propranolol for 48 hours
followed by oral propranolol until discharge, in 102 patients undergoing cardiac surgery.
Amiodarone was superior to propranolol in preventing postoperative AF, but beta-blocker
treatment was continued throughout the study in the patients assigned to amiodarone who
took beta-blockers before surgery. Thus, in many cases, the true comparison was amiodarone
plus beta-blocker versus beta-blocker alone, rather than amiodarone versus beta-blocker.
With regard to serious adverse events in our study, one patient in each group died during
the 48-hour follow-up. In addition, one patient in the metoprolol group had a stroke. In all of
these cases, the study medication was unlikely to be related to these adverse events. Both
treatments seemed to be well tolerated. No patients required crossover to the other
treatment. The only symptomatic adverse effect was venous thrombophlebitis in 11 patients
in the amiodarone group. The study drug infusion was temporarily interrupted because of
hypotension more often in the metoprolol group than in the amiodarone group and because
of bradycardia more often (although nonsignificantly) in the amiodarone group than in the
metoprolol group. These findings are in line with those of an earlier study reporting that
amiodarone infusion was associated with bradycardia and interruption of the infusion in
18% of patients (Jafari-Fresharaki et al. 1998).
An  obvious  limitation  in  our  study  is  that  although  the  incidence  of  AF  was  similar  (38
and 39 patients in the metoprolol and amiodarone groups, respectively) and did not differ
between the study groups, we lacked sufficient power to demonstrate equality. Even after
adjustment for potential confounders, the wide range in the confidence intervals (95% CI,
0.67–1.76) does not allow us to conclude that the two treatments were equally effective in
preventing postoperative AF. Thus, we cannot exclude the possibility that true differences in
efficacy exist between amiodarone and beta-blockers in the prevention of AF. For example, it
is possible that the withdrawal of established beta-blocker therapy for patients allocated to
amiodarone may have precipitated AF. Although we doubt this was the case, because
amiodarone has beta-blocking properties (Singh 2008), we cannot exclude the possibility that
this may have biased our results against amiodarone. The blocking effect of amiodarone is
supported by our finding that bradycardia (<60 beats/min) developed more frequently in
patients treated with amiodarone than in those treated with metoprolol. Our patients were
not considered to be at particularly elevated risk for AF and were hemodynamically stable,
were off pressors, and were free of mechanical ventilation within 24 hours of cardiac surgery.
Thus,  our  results  cannot  be  safely  applied to  sicker  patients  or  those  at  higher  risk  for  AF,
such as patients with a history of AF or undergoing mitral valve repair.
The study period of 48 hours starting from the first postoperative morning may be
thought to be too short. The incidence of AF is highest on the second and third postoperative
days (Arankiet al. 1996, Hakal et al. 2002). A great majority of this time period was well
covered in our study. As many as 17% of the patients developed AF after the study period
but before hospital discharge. However, the occurrence of AF after the study period did not
differ between the groups.
It  could  also  be  argued  that  the  amiodarone  dose  in  our  study  was  not  sufficient.
Amiodarone  has  been  shown  to  be  efficient  in  various  doses  and  in  oral  and  intravenous
administration (Crystal et al. 2002, Burgess et al. 2006, Aasbo et al. 2005, Gillespie et al. 2005,
Mitchell et al. 2005, Buckley et al. 2007). In the largest randomized trial, the amiodarone dose
was 10 mg/kg, whereas it was 50% more in our study, 15 mg/kg per day (Mitchell et al. 2005).
Thus, an insufficient dose is unlikely to explain the results of our study.
Although we did not find any difference in the incidence of AF, larger multicenter trials or
meta-analyses are needed to confirm the equality of metoprolol and amiodarone in
preventing postoperative AF. In addition, comparisons of metoprolol and amiodarone are
needed in patient cohorts with higher risk for AF, such as patients undergoing mitral
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operation, patients with a history of AF, and patients who are not hemodynamically stable
after operation. Until more data are available, we recommend adherence to current
guidelines, namely the use of beta-blockers as first-line prophylaxis of postoperative AF.
We conclude that while the observed incidence of AF during 48 hours of treatment with
intravenous metoprolol or amiodarone after cardiac surgery was similar, we cannot conclude
that the treatments are equally effective.
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7 SUMMARY AND CONCLUSIONS
AF  is  the  most  common  arrhythmia  to  occur  after  cardiac  surgery.  It  is  associated  with
postoperative complications, including increased risk of stroke, prolonged hospital stay and
increased costs. The purpose of our study was to find a reliable, effective, safe and well
tolerated tool for the prevention of postoperative AF after cardiac surgery.
In study I we randomized 240 patients to receive either oral or intravenous metoprolol for
48 hours after cardiac surgery. The incidence of postoperative AF was significantly lower in
the intravenonous metoprolol group (16.8%) than in the oral group (28.1%, p=0.036).
In study II a total of 241 patients were scheduled to receive either intravenous
hydrocortisone or placebo postoperatively for 84 hours. The incidence of postoperative AF
was 30.0% in the hydrocortisone group compared with 47.9% in the placebo group, and the
relative risk reduction was 37%.
In study III intravenous metoprolol therapy was shown to be as effective as intravenous
amiodarone in the prevention of AF after cardiac surgery. Altogether 316 patients were
randomized to receive either metoprolol or amiodarone intravenously starting on the first
postoperative morning after cardiac surgery. The incidence of postoperative atrial fibrillation
was 23.9% in the metoprolol group and 24.8% in the amiodarone group, with no statistical
difference between the groups.
On the basis of the these studies, the following conclusions can be drawn:
1. Intravenously administered metoprolol therapy is more effective than oral metoprolol
therapy after cardiac surgery. Intravenous metoprolol administration was feasible and
easy, and  turned out to be well tolerated in postoperative patients.
2. Intravenous hydrocortisone administration is highly effective in the prevention of AF
after cardiac surgery. Intravenous hydrocortisone therapy turned out to be feasible and
well tolerated. In addition, we found no serious complication associated with
intravenous corticosteroid therapy.
3. The occurrence of AF was similar in the metoprolol and amiodarone groups. However,
because of the wide range of the confidence intervals, we cannot conclude that
intravenous metoprolol and amiodarone are equally effective in the prevention of AF
after cardiac surgery.
We suggest that intravenous metoprolol therapy should be part of the routine medication
to prevent AF in all patients undergoing cardiac surgery, unless contraindicated. Moderate-
dosage corticosteroid (hydrocortisone) should be considered for the prevention of AF in high
risk patients undergoing cardiac surgery. Amiodarone should be used for the prevention of
postoperative AF only if beta-blocker therapy is contraindicated.
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Atrial fibrillation (AF) is the most 
common arrhythmia to occur after 
cardiac surgery. It is associated with 
postoperative complications including 
increased risk of stroke, prolonged 
hospital stay and increased costs. The 
study consisted of three randomized, 
prospective trials. In the first study 
intravenous metoprolol showed to be 
more effective than oral metoprolol 
in the prevention of AF after cardiac 
surgery. In the second study intrave-
nous hydrocortisone reduced the risk 
of postoperative AF by 37 % compared 
with placebo. In study three intrave-
nous metoprolol therapy showed to be 
as effective as intravenous amiodar-
one in the prevention of postoperative 
AF after cardiac surgery.
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